foscarnet has been researched along with Cytomegalovirus in 289 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Cytomegalovirus: A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-eight patients who provided 2 consecutive blood samples that tested positive for cytomegalovirus DNA by polymerase chain reaction (PCR) were randomized to receive either full-dose ganciclovir (5 mg/kg intravenously [iv] twice daily) or half-dose ganciclovir (5 mg/kg iv once daily) plus half-dose foscarnet (90 mg/kg iv once daily) for 14 days." | 9.11 | A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. ( Amooty, G; Brown, VS; Burroughs, AK; Emery, VC; Geretti, AM; Grace, SC; Griffiths, PD; Hainsworth, EG; Hassan-Walker, AF; Mattes, FM; Nebbia, G; Okwuadi, S; Potter, M; Prentice, G; Sabin, C; Sweny, P, 2004) |
| "The clinical significance of cytomegalovirus (CMV) foscarnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis." | 9.10 | Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. ( Chou, S; Crumpacker, C; Forman, MS; Jabs, DA; Lurain, NS; Martin, BK; Weinberg, A, 2003) |
| "A randomized open-label phase 2 trial compared the virological and clinical effects on cytomegalovirus (CMV) infection of a 14-day course of intravenous foscarnet (100 mg/[kg x 12 h]) or no treatment in 42 HIV-infected patients with < 100 CD4 cells/mm3 and persistent asymptomatic CMV viremia." | 9.09 | Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group. ( Aboulker, JP; Brun-Vézinet, F; Carrière, I; Fillet, AM; Gérard, L; Houhou, N; Leport, C; Ostinelli, J; Salmon-Céron, D; Vildé, JL, 1999) |
| "Patients with symptomatic gastrointestinal disease due to cytomegalovirus (CMV) were randomized to receive open-label ganciclovir (22) or foscarnet (26)." | 9.08 | Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. ( Benhamou, Y; Blanshard, C; Dohin, E; Gazzard, BG; Katlama, C; Lernestedt, JO, 1995) |
| "Four intravenous dosages of foscarnet given for 10 days were compared with no therapy in persons with AIDS who had asymptomatic cytomegalovirus (CMV) viremia." | 9.08 | Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. ( Acosta, EP; Balfour, HH; Boivin, G; Crumpacker, CS; Eaton, CA; Erice, A; Fletcher, CV; Henry, WK; Holm, MA; Martin-Munley, SS; Shepp, DH; Smith, SA, 1996) |
| "The aim of this study was to investigate peripheral blood polymorphonuclear leukocytes and, whenever possible, aqueous humor from 65 AIDS patients with ophthalmoscopically diagnosed human cytomegalovirus (HCMV) retinitis to determine (i) whether patients consistently carry viral DNA and (ii) to what extent foscarnet induction treatment decreases viral DNA levels." | 9.07 | Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group. ( Baldanti, F; Furione, M; Gerna, G; Percivalle, E; Revello, MG; Sarasini, A; Zella, D; Zipeto, D, 1994) |
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 9.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 8.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Ganciclovir (GCV) and foscarnet (FCN) are effective anti-cytomegalovirus (CMV) preemptive therapies; however, the impact of the 2 agents on various clinical outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) remains unclear." | 8.02 | Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy. ( Iida, H; Ino, K; Kajiguchi, T; Kasahara, S; Kasai, M; Kohno, A; Kurahashi, S; Kusumoto, S; Miyao, K; Morishita, T; Murata, M; Nishida, T; Ozawa, Y; Sawa, M; Takami, A; Terakura, S, 2021) |
| "Herein, we phenotypically and enzymatically characterize the theoretical mutation Q579I in helix K and the already described clinical mutation K805Q in helix P of cytomegalovirus DNA polymerase for susceptibility to foscarnet." | 7.96 | Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase. ( Boivin, G; Pham, VD; Piret, J; Shi, R; Zarrouk, K, 2020) |
| "This single-center, retrospective study included immunosuppressed adults with CMV viremia who received foscarnet between January 2012-July 2017." | 7.91 | Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy. ( Athans, V; Koval, CE; Lam, SW; Spinner, ML, 2019) |
| "We studied 97 patients who developed cytomegalovirus (CMV) viremia following an allogeneic hemopoietic stem cell transplant (HSCT) between 2010 and 2015, treated with foscarnet, with the aim of assessing efficacy and safety." | 7.88 | Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants. ( Angelucci, E; Bacigalupo, A; Bregante, S; Chiusolo, P; Dominietto, A; Laurenti, L; Metafuni, E; Sica, S; Van Lint, MT, 2018) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 7.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Human cytomegalovirus UL54 DNA polymerase gene mutations that confer foscarnet resistance in clinical practice typically cluster in the amino terminal 2, palm and finger domains." | 7.85 | Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. ( Chou, S, 2017) |
| "Ganciclovir-resistant cytomegalovirus (GCV-R CMV) is an emerging challenge among solid organ transplant (SOT) recipients." | 7.83 | Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study. ( Angarone, M; Flaherty, J; Ison, MG; Penugonda, S; Rubin, J; Stosor, V; Young, PG, 2016) |
| "The methylenecyclopropane nucleoside (MCPN) analogs synguanol and its 6-alkoxy (MBX2168) and 6-alkylthio (MBX1616) derivatives retained good in vitro activities against several common ganciclovir-resistant UL97 kinase variants of human cytomegalovirus." | 7.80 | Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives. ( Bowlin, TL; Chou, S; Komazin-Meredith, G; Williams, JD, 2014) |
| "(Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation." | 7.79 | The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. ( Cunha-Bang, Cd; Frederiksen, CM; Gustafsson, F; Iversen, M; Kirkby, N; Kjaer, J; Lepri, AC; Lundgren, JD; Rasmussen, A; Sengeløv, H; Sønderholm, M; Sørensen, SS, 2013) |
| "Human cytomegalovirus (CMV) UL54 DNA polymerase (pol) mutants with known patterns of resistance to current antivirals ganciclovir (GCV), foscarnet (FOS), and cidofovir (CDV) were tested for cyclopropavir (CPV) susceptibility by a standardized reporter-based yield reduction assay." | 7.78 | Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. ( Bowlin, TL; Chou, S; Marousek, G, 2012) |
| "A patient with systemic cytomegalovirus (CMV), including chorioretinitis, received localized and systemic ganciclovir, systemic cidofovir analog, and localized foscarnet." | 7.78 | Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma. ( Chavala, S; Miller, MB; Moss, HB; Say, E, 2012) |
| "Foscarnet (FOS) is a pyrophosphate analogue that inhibits both cytomegalovirus (CMV) and human immunodeficiency virus (HIV) replication." | 7.78 | Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. ( Agut, H; Boutolleau, D; Burrel, S; Canestri, A; Clavel-Osorio, C; Katlama, C; Marcelin, AG; Seang, S; Wirden, M, 2012) |
| "Cytomegalovirus (CMV) infections in kidney transplant recipients are in most cases successfully treated with oral valganciclovir (VGCV)." | 7.77 | Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. ( Asberg, A; Hartmann, A; Haug Dorenberg, D; Kristiansen, KI; Leivestad, T; Myhre, HA; Rollag, H, 2011) |
| "Selection of human cytomegalovirus variants in the presence of ganciclovir or foscarnet led to 18 DNA polymerase mutations, 14 of which had not been previously studied." | 7.77 | Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. ( Azzi, A; Boivin, G; Gilbert, C; Goyette, N; Lin, SX, 2011) |
| "Phenotypic characterisation of the human cytomegalovirus (HCMV) pUL54 DNA polymerase is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to foscarnet." | 7.74 | Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet. ( Alain, S; Ducancelle, A; Mazeron, MC; Petit, F; Sanson Le Pors, MJ, 2007) |
| "Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients with advanced age." | 7.74 | Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. ( Hori, A; Kami, M; Kato, D; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Morinaga, S; Murashige, N; Narimatsu, H; Shibata, T; Taniguchi, S; Wake, A; Yuji, K, 2007) |
| "Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality after lung transplantation despite ganciclovir prophylaxis." | 7.74 | A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. ( Hanson, KE; Palmer, SM; Reddy, AJ; Zaas, AK, 2007) |
| "A phenotypic method was developed to test mutations in the human cytomegalovirus (HCMV) DNA polymerase gene (UL54) suspected to confer resistance to foscarnet." | 7.73 | Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet. ( Alain, S; Ducancelle, A; Fillet, AM; Gravisse, J; Mazeron, MC; Petit, F; Pors, MJ, 2005) |
| "Mutations in the human cytomegalovirus DNA polymerase (UL54) can not only decrease but also increase susceptibility to the pyrophosphate (PP(i)) analogue foscarnet." | 7.73 | Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet. ( Boivin, G; Gilbert, C; Götte, M; Tchesnokov, EP, 2006) |
| "Foscarnet is currently licensed for the treatment of human cytomegalovirus (HCMV) infection." | 7.73 | A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( Alain, S; Champier, G; Ducancelle, A; Le Pors, MJ; Mazeron, MC; Petit, F, 2006) |
| "Foscarnet (PFA) and ganciclovir (GCV) were used to induce mutants of the human cytomegalovirus (HCMV) Towne strain." | 7.72 | Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase. ( Brytting, M; Mousavi-Jazi, M; Schloss, L; Wahren, B, 2003) |
| "Ganciclovir-resistant (GCV-R) cytomegalovirus (CMV) is now being reported with increasing frequency in solid organ transplant recipients." | 7.71 | Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. ( Avery, RK; Braun, W; Flechner, SM; Goldman, M; Gordon, SM; Haug, M; Isada, CM; Kohn, D; Long, J; Longworth, DL; Lurain, NS; Maurer, J; Mawhorter, SD; Mossad, SB; Schilz, R; Schmitt, SK; Taege, AJ; Yen-Lieberman, B, 2002) |
| "We report three pediatric patients with ganciclovir-resistant cytomegalovirus (CMV) retinitis who were successfully treated with foscarnet." | 7.71 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA. ( Amo, K; Aono, T; Hara, J; Kim, JY; Matsuda, Y; Miyagawa, H; Ohta, H; Okada, S; Sashihara, J; Sawada, A; Tanaka-Taya, K; Tano, Y; Tokimasa, S; Yamamoto, S; Yamanishi, K, 2001) |
| "Ganciclovir is the drug of choice for the treatment of acute cytomegalovirus infections." | 7.71 | [In vitro susceptibility to ganciclovir and foscarnet of cytomegaloviruses]. ( Herrero, M; Labeaga, R; Margall, R; Muñoz, JM; Otegui, M; Prats, G; Rabella, N, 2001) |
| "The resistance of cytomegalovirus (CMV) to ganciclovir is a factor in therapeutic failure and disease progression." | 7.71 | Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. ( Fishman, JA; Kallas, WM; Mylonakis, E, 2002) |
| "Three human immunodeficiency virus-infected subjects with progressive cytomegalovirus (CMV) retinitis despite prolonged antiviral therapy had buffy coat CMV isolates that were resistant to both ganciclovir and foscarnet." | 7.70 | Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. ( Chou, S; Drew, WL; Gordon, SM; LaVoy, AG; Marousek, G; Miner, RC; Parenti, DM; Ross, JG, 1998) |
| "In a previous study, we reported that 1-O-octadecyl-sn-glycero-3-foscarnet (ODG-PFA) was 40 to 93 times more potent than free foscarnet (PFA) in human cytomegalovirus (HCMV)-, herpes simplex virus type 1 (HSV-1)- and human immunodeficiency virus type 1 (HIV-1)-infected cells." | 7.70 | Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells. ( Aldern, KA; Beadle, JR; Gardner, MF; Hostetler, KY; Kini, GD; Richman, DD; Wright, KN, 1998) |
| " Antiviral susceptibility testing of blood cytomegaloviral isolates was done when patients failed to respond to intravenous ganciclovir treatment for symptomatic cytomegalovirus infection." | 7.70 | Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. ( Boeckh, M; Corey, L; Davis, CL; Koelle, DM; Limaye, AP, 2000) |
| "Foscarnet-resistant cytomegalovirus (ID50 > 300 microM) was isolated from two patients, one of whom was being treated with foscarnet." | 7.69 | Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. ( Apuzzo, L; Charache, P; Dunn, JP; Forman, MS; Jabs, DA; MacCumber, MW, 1995) |
| "A rapid screening assay for the detection of resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples was developed by using single doses of both drugs and an immediate-early antigen plaque reduction assay." | 7.69 | Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples. ( Baldanti, F; Gerna, G; Percivalle, E; Revello, MG; Sarasini, A; Zavattoni, M, 1995) |
| "To determine if ganciclovir given three times per week post-transplant is tolerable and effective for prevention of cytomegalovirus (CMV) infection in recipients of T cell-depleted marrow from related or unrelated donors, we have used ganciclovir 2." | 7.69 | Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. ( Andersson, B; Deisseroth, AB; Giralt, S; Goodrich, J; Ippoliti, C; Luna, M; Mehra, R; Panina, A; Przepiorka, D; van Besien, K, 1994) |
| "Foscarnet is a pyrophosphate analogue that possesses substantial activity against human cytomegalovirus (HCMV) in patients with CMV retinitis." | 7.69 | In vitro anti-human cytomegalovirus activity of liposome-encapsulated foscarnet. ( Cinatl, J; Doerr, HW; Gümbel, HO; Ohrloff, C; Rabenau, H; Rückert, DG, 1994) |
| "Antiviral activity of L-ascorbic acid-2-phosphate (ASC-2P), a long-acting derivative of L-ascorbic acid, against several human cytomegalovirus (CMV) strains was examined in cultures of human foreskin fibroblasts (HFF) and endothelial cells (EC)." | 7.69 | In vitro inhibition of human cytomegalovirus replication in human foreskin fibroblasts and endothelial cells by ascorbic acid 2-phosphate. ( Chenot, JF; Cinatl, J; Doerr, HW; Encke, A; Gümbel, HO; Rabenau, H; Scholz, M; Weber, B, 1995) |
| "Four human cytomegalovirus (HCMV) isolates from four different AIDS patients treated with both ganciclovir and foscarnet and not responding clinically to antiviral treatment, were studied in order to verify the occurrence of double resistance to both drugs, and to define whether single or multiple HCMV strains could be responsible for the double resistance." | 7.69 | Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. ( Baldanti, F; Barbi, M; Brerra, R; Furione, M; Gerna, G; Percivalle, E; Sarasini, A, 1995) |
| "Three human cytomegalovirus (HCMV) strains (VR4760, VR4955, and VR5120) showing double resistance to ganciclovir (GCV) and foscarnet (PFA) were isolated from three patients with AIDS who underwent multiple sequential courses of therapy with GCV and PFA (A." | 7.69 | Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered f ( Baldanti, F; Biron, KK; Chou, S; Gerna, G; Sarasini, A; Silini, E; Stanat, SC; Underwood, MR, 1996) |
| "To determine the efficacy of combined ganciclovir and foscarnet intravitreal injections in controlling clinically resistant cytomegalovirus retinitis in a 37-year-old man with the acquired immunodeficiency syndrome who refused systemic therapy." | 7.69 | Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. ( Desatnik, HR; Foster, RE; Lowder, CY, 1996) |
| "Four human cytomegalovirus strains with double resistance to both ganciclovir and foscarnet were recovered from acquired immunodeficiency syndrome (AIDS) patients." | 7.69 | Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. ( Baldanti, F; Barbi, M; Biron, KK; Gerna, G; Lazzarin, A; Sarasini, A; Silini, E, 1995) |
| "In a previous study, we showed that patients undergoing allogeneic hemopoietic stem cell transplantation (HSCT) who had cytomegalovirus (CMV) antigenemia with more than 4 CMV antigen-positive cells/200,000 have a high transplant-related mortality (TRM) rate, despite treatment with ganciclovir or foscarnet." | 7.69 | Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. ( Bacigalupo, A; Bregante, S; Gualandi, F; Isaza, A; Lamparelli, T; Marmont, AM; Occhini, D; Tedone, E; Trespi, G; Van Lint, MT, 1996) |
| "Cytomegalovirus (CMV) infection is still a problem for organ transplant recipients despite studies that long-term prophylaxis with high dose of acyclovir or ganciclovir given to all organ recipients may limit the consequences of infection and disease." | 7.69 | Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. ( Baruzzo, S; Gotti, E; Moioli, F; Perani, V; Remuzzi, G; Suter, F, 1996) |
| "The human cytomegalovirus (HCMV) gene UL97 product was shown to play an important role in phosphorylation of ganciclovir (GCV) in HCMV-infected cells." | 7.68 | Rapid detection of cytomegalovirus strains resistant to ganciclovir through mutations within the gene UL97. ( Alain, S; Mazeron, MC; Morinet, F; Pépin, JM; Raskine, L; Sanson-Le Pors, MJ, 1993) |
| "Clinical isolates of human cytomegalovirus (HCMV) were screened for susceptibility to ganciclovir by plaque-reduction assay and in situ ELISA." | 7.68 | A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. ( Lurain, NS; Tatarowicz, WA; Thompson, KD, 1992) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 7.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Investigations of mutants of human cytomegalovirus (CMV) that are resistant to foscarnet could shed light on mechanisms of selective drug action and features of drug resistance that may be clinically important." | 7.68 | Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. ( Coen, DM; Sullivan, V, 1991) |
| "The antiviral effect of ganciclovir and foscarnet encapsulated in liposomes was studied against cytomegalovirus in human embryonic lung fibroblast cells." | 7.68 | Increased efficacy of ganciclovir and foscarnet inhibition of cytomegalovirus replication in vitro by encapsulation in liposomes. ( Bakker-Woudenberg, IA; Lokerse, AF; ten Kate, M, 1990) |
| "Ganciclovir and foscarnet possess substantial activity against cytomegalovirus." | 7.68 | Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. ( Lane, HC; Manischewitz, JF; Quinnan, GV; Wittek, AE, 1990) |
| "Eight patients, 7 renal and 1 combined renal and pancreas allograft recipients with generalized cytomegalovirus (CMV) infection were treated with continuous intravenous foscarnet infusion (0." | 7.67 | Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants. ( Akesson-Johansson, A; Andersson, J; Brattström, C, 1989) |
| "The antiviral activity of trifluorothymidine (TFT) singly and in combination with other antiviral agents against human cytomegalovirus (HCMV) was evaluated by using an infectious center plaque reduction assay." | 7.66 | Inhibition of human cytomegalovirus by trifluorothymidine. ( Kelley, E; Spector, SA; Tyndall, M, 1983) |
| "Foscarnet is a reasonable first line anti CMV agent in this setting." | 6.46 | CMV-related thrombocytopenia treated with foscarnet: a case series and review of the literature. ( Chajek-Shaul, T; Hershcovici, T; Koslowsky, B; Wolf, D; Yaari, S, 2010) |
| "The DNA polymerase of human herpes viruses, including cytomegalovirus (CMV), and the reverse transcriptase of human immunodeficiency virus (HIV) are selectively inhibited in vitro by the pyrophosphate analogue foscarnet." | 6.17 | Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. ( Bryson, HM; Wagstaff, AJ, 1994) |
| "In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomized 2:1 to maribavir 400 mg twice daily or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for 8 weeks, with 12 weeks of follow-up." | 5.51 | Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. ( Alain, S; Alexander, BD; Avery, RK; Blumberg, EA; Chemaly, RF; Cordonnier, C; Duarte, RF; Florescu, DF; Fournier, M; Kamar, N; Kumar, D; Maertens, J; Marty, FM; Papanicolaou, GA; Silveira, FP; Sundberg, AK; Witzke, O; Wu, J, 2022) |
| "Although mortality was high in this population, foscarnet use, with proper precautions, was generally safe and significant renal dysfunction was lower than previously reported in other sources, even with extended use." | 5.48 | Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study. ( Allen, A; Ison, MG; Lacloche, L; Pierce, B; Richardson, CL, 2018) |
| "Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking." | 5.43 | Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. ( Ariza-Heredia, E; Chemaly, RF; Doan, V; El Chaer, F; Jan, A; Mori, N; Oliver, N; Shah, D; Tayar, J; Tverdek, F; Wang, E, 2016) |
| "Literature search was performed on PubMed with keywords cytomegalovirus, transplantation, ganciclovir, valganciclovir, maribavir, letermovir, cidofovir, and foscarnet." | 5.41 | Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients. ( Razonable, RR, 2023) |
| "Foscarnet was discontinued because of concern about its potential central nervous system toxicity." | 5.31 | Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient. ( Balfour, HH; Clark, HB; Holman, CJ; Julin, JE; Krivit, W; van Burik, JH; Webb, C, 2002) |
| "Foscarnet was not liberated on incubation of n-tetradecyl 6-O-carboxyphosphonyl-alpha-D-glucopyranoside with rat liver or intestine homogenate, neither could the neoglycolipid conjugate nor foscarnet be detected in rat plasma following oral administration." | 5.30 | Neoglycolipid conjugates of foscarnet with enhanced antiviral activity in cells infected with human cytomegalovirus and herpes simplex virus type 1. ( Dypbukt, J; Ljungdahl-Ståhle, E; Maloisel, JL; Pring, BG; Tidén, AK, 1999) |
| "A concomitant treatment of cytomegalovirus infections, such as cytomegalovirus retinitis, with phosphonoformate in patients with acquired immunodeficiency syndrome receiving 3'-azido-3'-deoxythymidine may be appropriate, and this combination may also be useful in controlling human immunodeficiency virus infection." | 5.28 | Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. ( Eriksson, BF; Schinazi, RF, 1989) |
| " The antiCMV activity of acyclovir in combination with human fibroblast interferon (IFN-beta), phosphonoformic acid (PFA), or trifluorothymidine (TFT) was therefore evaluated." | 5.26 | Effects of acyclovir combined with other antiviral agents on human cytomegalovirus. ( Kelley, E; Spector, SA; Tyndall, M, 1982) |
| "Forty-eight patients who provided 2 consecutive blood samples that tested positive for cytomegalovirus DNA by polymerase chain reaction (PCR) were randomized to receive either full-dose ganciclovir (5 mg/kg intravenously [iv] twice daily) or half-dose ganciclovir (5 mg/kg iv once daily) plus half-dose foscarnet (90 mg/kg iv once daily) for 14 days." | 5.11 | A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. ( Amooty, G; Brown, VS; Burroughs, AK; Emery, VC; Geretti, AM; Grace, SC; Griffiths, PD; Hainsworth, EG; Hassan-Walker, AF; Mattes, FM; Nebbia, G; Okwuadi, S; Potter, M; Prentice, G; Sabin, C; Sweny, P, 2004) |
| "The clinical significance of cytomegalovirus (CMV) foscarnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis." | 5.10 | Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. ( Chou, S; Crumpacker, C; Forman, MS; Jabs, DA; Lurain, NS; Martin, BK; Weinberg, A, 2003) |
| "To evaluate the efficacy and safety of the foscarnet-ganciclovir combination in induction therapy (IT) and maintenance therapy (MT) for cytomegalovirus (CMV) central neurological disorders in HIV-infected patients." | 5.09 | Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. ( Anduze-Faris, BM; Boukli, N; Caumes, E; Costagliola, D; Fillet, AM; Gasnault, J; Gozlan, J; Katlama, C; Lancar, R; Leport, C; Livartowsky, J; Matheron, S; Salmon, D, 2000) |
| "A randomized open-label phase 2 trial compared the virological and clinical effects on cytomegalovirus (CMV) infection of a 14-day course of intravenous foscarnet (100 mg/[kg x 12 h]) or no treatment in 42 HIV-infected patients with < 100 CD4 cells/mm3 and persistent asymptomatic CMV viremia." | 5.09 | Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group. ( Aboulker, JP; Brun-Vézinet, F; Carrière, I; Fillet, AM; Gérard, L; Houhou, N; Leport, C; Ostinelli, J; Salmon-Céron, D; Vildé, JL, 1999) |
| "Patients with symptomatic gastrointestinal disease due to cytomegalovirus (CMV) were randomized to receive open-label ganciclovir (22) or foscarnet (26)." | 5.08 | Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. ( Benhamou, Y; Blanshard, C; Dohin, E; Gazzard, BG; Katlama, C; Lernestedt, JO, 1995) |
| "Four intravenous dosages of foscarnet given for 10 days were compared with no therapy in persons with AIDS who had asymptomatic cytomegalovirus (CMV) viremia." | 5.08 | Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. ( Acosta, EP; Balfour, HH; Boivin, G; Crumpacker, CS; Eaton, CA; Erice, A; Fletcher, CV; Henry, WK; Holm, MA; Martin-Munley, SS; Shepp, DH; Smith, SA, 1996) |
| "The aim of this study was to investigate peripheral blood polymorphonuclear leukocytes and, whenever possible, aqueous humor from 65 AIDS patients with ophthalmoscopically diagnosed human cytomegalovirus (HCMV) retinitis to determine (i) whether patients consistently carry viral DNA and (ii) to what extent foscarnet induction treatment decreases viral DNA levels." | 5.07 | Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group. ( Baldanti, F; Furione, M; Gerna, G; Percivalle, E; Revello, MG; Sarasini, A; Zella, D; Zipeto, D, 1994) |
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 5.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| "Ganciclovir (GCV), the therapy of choice for human cytomegalovirus (CMV) infections and foscarnet, a drug used to treat GCV-resistant CMV infections was approved more than twenty years ago." | 4.87 | The search for new therapies for human cytomegalovirus infections. ( Kern, ER; Prichard, MN, 2011) |
| "Many clinicians are under the impression that the combination of ganciclovir (GCV) and foscarnet is synergistic versus cytomegalovirus (CMV) and/or that combination therapy might prevent the emergence of resistance to one or both antivirals." | 4.83 | Is combination antiviral therapy for CMV superior to monotherapy? ( Drew, WL, 2006) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 4.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Ganciclovir (GCV) and foscarnet (FCN) are effective anti-cytomegalovirus (CMV) preemptive therapies; however, the impact of the 2 agents on various clinical outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) remains unclear." | 4.02 | Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy. ( Iida, H; Ino, K; Kajiguchi, T; Kasahara, S; Kasai, M; Kohno, A; Kurahashi, S; Kusumoto, S; Miyao, K; Morishita, T; Murata, M; Nishida, T; Ozawa, Y; Sawa, M; Takami, A; Terakura, S, 2021) |
| "Letermovir (LTV) might be an alternative treatment to nephrotoxic foscarnet (FOS) in Ganciclovir (GCV) resistant cytomegalovirus (CMV) infection." | 4.02 | Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients. ( Müller, TF; Näf, B; Rho, E; Schachter, T; von Moos, S; Wüthrich, RP, 2021) |
| "Herein, we phenotypically and enzymatically characterize the theoretical mutation Q579I in helix K and the already described clinical mutation K805Q in helix P of cytomegalovirus DNA polymerase for susceptibility to foscarnet." | 3.96 | Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase. ( Boivin, G; Pham, VD; Piret, J; Shi, R; Zarrouk, K, 2020) |
| "This single-center, retrospective study included immunosuppressed adults with CMV viremia who received foscarnet between January 2012-July 2017." | 3.91 | Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy. ( Athans, V; Koval, CE; Lam, SW; Spinner, ML, 2019) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 3.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Human cytomegalovirus UL54 DNA polymerase gene mutations that confer foscarnet resistance in clinical practice typically cluster in the amino terminal 2, palm and finger domains." | 3.85 | Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. ( Chou, S, 2017) |
| "Ganciclovir-resistant cytomegalovirus (GCV-R CMV) is an emerging challenge among solid organ transplant (SOT) recipients." | 3.83 | Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study. ( Angarone, M; Flaherty, J; Ison, MG; Penugonda, S; Rubin, J; Stosor, V; Young, PG, 2016) |
| "Eight in vitro selection experiments under brincidofovir pressure elicited the known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L and the novel exonuclease domain substitutions D413Y, E303D, and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir or 17-fold when E303G was combined with V812L." | 3.83 | Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. ( Chou, S; Ercolani, RJ; Lanier, ER, 2016) |
| "The methylenecyclopropane nucleoside (MCPN) analogs synguanol and its 6-alkoxy (MBX2168) and 6-alkylthio (MBX1616) derivatives retained good in vitro activities against several common ganciclovir-resistant UL97 kinase variants of human cytomegalovirus." | 3.80 | Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives. ( Bowlin, TL; Chou, S; Komazin-Meredith, G; Williams, JD, 2014) |
| "Preemptive therapy with ganciclovir (GCV) based on the results of a cytomegalovirus (CMV) antigenemia assay is a standard strategy for preventing CMV disease after allogeneic hematopoietic cell transplantation (HCT)." | 3.79 | Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides. ( Ashizawa, M; Ishihara, Y; Kako, S; Kanda, J; Kanda, Y; Kawamura, K; Kikuchi, M; Kimura, S; Machishima, T; Nakasone, H; Nishida, J; Sakamoto, K; Sato, M; Tanihara, A; Terasako-Saito, K; Wada, H; Yamasaki, R; Yamazaki, R, 2013) |
| "(Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation." | 3.79 | The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. ( Cunha-Bang, Cd; Frederiksen, CM; Gustafsson, F; Iversen, M; Kirkby, N; Kjaer, J; Lepri, AC; Lundgren, JD; Rasmussen, A; Sengeløv, H; Sønderholm, M; Sørensen, SS, 2013) |
| "Human cytomegalovirus (CMV) UL54 DNA polymerase (pol) mutants with known patterns of resistance to current antivirals ganciclovir (GCV), foscarnet (FOS), and cidofovir (CDV) were tested for cyclopropavir (CPV) susceptibility by a standardized reporter-based yield reduction assay." | 3.78 | Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. ( Bowlin, TL; Chou, S; Marousek, G, 2012) |
| "A patient with systemic cytomegalovirus (CMV), including chorioretinitis, received localized and systemic ganciclovir, systemic cidofovir analog, and localized foscarnet." | 3.78 | Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma. ( Chavala, S; Miller, MB; Moss, HB; Say, E, 2012) |
| "Foscarnet (FOS) is a pyrophosphate analogue that inhibits both cytomegalovirus (CMV) and human immunodeficiency virus (HIV) replication." | 3.78 | Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. ( Agut, H; Boutolleau, D; Burrel, S; Canestri, A; Clavel-Osorio, C; Katlama, C; Marcelin, AG; Seang, S; Wirden, M, 2012) |
| "Phosphonoformic acid (PFA, foscarnet) belongs to a class of antiviral drugs that inhibit the human cytomegalovirus DNA polymerase (UL54) by mimicking the pyrophosphate leaving group of the nucleotide transfer reaction." | 3.77 | Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase. ( Doublié, S; Götte, M; Tchesnokov, EP; Zahn, KE, 2011) |
| "Cytomegalovirus (CMV) infections in kidney transplant recipients are in most cases successfully treated with oral valganciclovir (VGCV)." | 3.77 | Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. ( Asberg, A; Hartmann, A; Haug Dorenberg, D; Kristiansen, KI; Leivestad, T; Myhre, HA; Rollag, H, 2011) |
| "Recombinant phenotyping of cytomegalovirus (CMV) pol region III mutations from clinical specimens showed that T813S and G841A each conferred foscarnet resistance and approximately threefold increased ganciclovir resistance; adding the UL97 mutation C592G increased ganciclovir resistance to approximately sixfold." | 3.74 | Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. ( Chou, S; Li, S; Marousek, GI; Van Wechel, LC; Weinberg, A, 2007) |
| "Phenotypic characterisation of the human cytomegalovirus (HCMV) pUL54 DNA polymerase is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to foscarnet." | 3.74 | Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet. ( Alain, S; Ducancelle, A; Mazeron, MC; Petit, F; Sanson Le Pors, MJ, 2007) |
| "Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients with advanced age." | 3.74 | Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. ( Hori, A; Kami, M; Kato, D; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Morinaga, S; Murashige, N; Narimatsu, H; Shibata, T; Taniguchi, S; Wake, A; Yuji, K, 2007) |
| "Human herpesvirus 6 (HHV-6), which is closely related to human cytomegalovirus, is sensitive to foscarnet (PFA)." | 3.74 | Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet. ( Agut, H; Bonnafous, P; Boutolleau, D; Gautheret-Dejean, A; Naesens, L; Petrella, S; Sougakoff, W, 2007) |
| "A human cytomegalovirus (CMV) UL54 pol exonuclease domain II mutation, D413A, found in a clinical specimen, conferred ganciclovir (GCV) and cidofovir resistance but not foscarnet resistance when incorporated into laboratory strain T2294." | 3.74 | Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. ( Chou, S; Marousek, GI, 2008) |
| "Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality after lung transplantation despite ganciclovir prophylaxis." | 3.74 | A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. ( Hanson, KE; Palmer, SM; Reddy, AJ; Zaas, AK, 2007) |
| "This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation." | 3.74 | Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. ( Caplan, O; Chou, S; Efferth, T; Lurain, NS; Marschall, M; Neumann, AU; Resnick, IB; Saleh, N; Shapira, MY; Stamminger, T; Wolf, DG, 2008) |
| "Diverse mutations in the cytomegalovirus (CMV) DNA polymerase (pol) gene confer resistance to one or more of the antiviral drugs ganciclovir, foscarnet or cidofovir." | 3.74 | Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. ( Chou, S; Li, S; Marousek, G; Weinberg, A, 2008) |
| "A phenotypic method was developed to test mutations in the human cytomegalovirus (HCMV) DNA polymerase gene (UL54) suspected to confer resistance to foscarnet." | 3.73 | Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet. ( Alain, S; Ducancelle, A; Fillet, AM; Gravisse, J; Mazeron, MC; Petit, F; Pors, MJ, 2005) |
| "Mutations in the human cytomegalovirus DNA polymerase (UL54) can not only decrease but also increase susceptibility to the pyrophosphate (PP(i)) analogue foscarnet." | 3.73 | Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet. ( Boivin, G; Gilbert, C; Götte, M; Tchesnokov, EP, 2006) |
| "Foscarnet is currently licensed for the treatment of human cytomegalovirus (HCMV) infection." | 3.73 | A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( Alain, S; Champier, G; Ducancelle, A; Le Pors, MJ; Mazeron, MC; Petit, F, 2006) |
| "Foscarnet (PFA) and ganciclovir (GCV) were used to induce mutants of the human cytomegalovirus (HCMV) Towne strain." | 3.72 | Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase. ( Brytting, M; Mousavi-Jazi, M; Schloss, L; Wahren, B, 2003) |
| "Ganciclovir-resistant (GCV-R) cytomegalovirus (CMV) is now being reported with increasing frequency in solid organ transplant recipients." | 3.71 | Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. ( Avery, RK; Braun, W; Flechner, SM; Goldman, M; Gordon, SM; Haug, M; Isada, CM; Kohn, D; Long, J; Longworth, DL; Lurain, NS; Maurer, J; Mawhorter, SD; Mossad, SB; Schilz, R; Schmitt, SK; Taege, AJ; Yen-Lieberman, B, 2002) |
| "We report three pediatric patients with ganciclovir-resistant cytomegalovirus (CMV) retinitis who were successfully treated with foscarnet." | 3.71 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA. ( Amo, K; Aono, T; Hara, J; Kim, JY; Matsuda, Y; Miyagawa, H; Ohta, H; Okada, S; Sashihara, J; Sawada, A; Tanaka-Taya, K; Tano, Y; Tokimasa, S; Yamamoto, S; Yamanishi, K, 2001) |
| "To determine the prevalence of the in vitro resistance rate of cytomegalovirus (CMV) to gancyclovir (GCV) and foscarnet (FOS) among patients with AIDS and chorioretinitis." | 3.71 | [Cytomegalovirus sensitivity to anti-retroviral agents in patients infected with the human immunodeficiency virus with chorioretinitis in Spain]. ( Cañizares, MA; Casado, JL; González, J; Guerrero, A; Losada, I; Pérez-Elías, MJ; Rubio, R, 2001) |
| "The resistance of cytomegalovirus (CMV) to ganciclovir is a factor in therapeutic failure and disease progression." | 3.71 | Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. ( Fishman, JA; Kallas, WM; Mylonakis, E, 2002) |
| "Three human immunodeficiency virus-infected subjects with progressive cytomegalovirus (CMV) retinitis despite prolonged antiviral therapy had buffy coat CMV isolates that were resistant to both ganciclovir and foscarnet." | 3.70 | Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. ( Chou, S; Drew, WL; Gordon, SM; LaVoy, AG; Marousek, G; Miner, RC; Parenti, DM; Ross, JG, 1998) |
| "The polymerase (pol) coding sequence was determined for 40 independent clinical cytomegalovirus isolates sensitive to ganciclovir and foscarnet." | 3.70 | Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. ( Cai, GY; Chou, S; Crumpacker, CS; Lurain, NS; Sharma, PL; Weinberg, A, 1999) |
| "To determine intraocular toxicity and efficacy of the lipid prodrug of foscarnet, 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA), as a long-acting, nontoxic intravitreous injectable drug delivery system for cytomegalovirus (CMV) retinitis." | 3.70 | Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug. ( Avila, CP; Bergeron-Lynn, G; Cheng, L; Freeman, WR; Gardner, MF; Hostetler, KY; Keefe, KS; Wiley, CA, 1999) |
| "A fatty acid derivative of ganciclovir (GCV), elaidic acid ganciclovir (E-GCV), has been evaluated for its inhibitory activity against laboratory and clinical strains of herpes simplex type 1 (HSV-1) and type 2 (HSV-2), varicella-zoster virus (VZV) and human cytomegalovirus (HCMV) in human embryonic lung fibroblasts." | 3.70 | Antiviral activity of ganciclovir elaidic acid ester against herpesviruses. ( Andrei, G; De Clercq, E; Myhren, F; Neyts, J; Sandvold, ML; Snoeck, R, 2000) |
| " Antiviral susceptibility testing of blood cytomegaloviral isolates was done when patients failed to respond to intravenous ganciclovir treatment for symptomatic cytomegalovirus infection." | 3.70 | Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. ( Boeckh, M; Corey, L; Davis, CL; Koelle, DM; Limaye, AP, 2000) |
| "A patient with AIDS and cytomegalovirus (CMV) retinitis received ganciclovir and foscarnet for 20 and 5 months, respectively, with evidence of periodic disease progression." | 3.70 | A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. ( Chou, S; Drew, WL; Miner, RC, 2000) |
| " We attempted to detect cytomegalovirus DNA in 19 vitreous samples from patients with the acquired immunodeficiency syndrome (AIDS) who had untreated cytomegalovirus retinitis and in 40 vitreous samples from patients with AIDS who had been treated with systemic ganciclovir or foscarnet, or both." | 3.69 | A sensitive and specific polymerase chain reaction-based assay for the diagnosis of cytomegalovirus retinitis. ( Ai, E; Irvine, AR; Kuppermann, BD; Luckie, AP; Margolis, TP; McCann, JD; Schwartz, DM; Wong, MG, 1995) |
| "Foscarnet-resistant cytomegalovirus (ID50 > 300 microM) was isolated from two patients, one of whom was being treated with foscarnet." | 3.69 | Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. ( Apuzzo, L; Charache, P; Dunn, JP; Forman, MS; Jabs, DA; MacCumber, MW, 1995) |
| "A rapid screening assay for the detection of resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples was developed by using single doses of both drugs and an immediate-early antigen plaque reduction assay." | 3.69 | Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples. ( Baldanti, F; Gerna, G; Percivalle, E; Revello, MG; Sarasini, A; Zavattoni, M, 1995) |
| "To determine if ganciclovir given three times per week post-transplant is tolerable and effective for prevention of cytomegalovirus (CMV) infection in recipients of T cell-depleted marrow from related or unrelated donors, we have used ganciclovir 2." | 3.69 | Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. ( Andersson, B; Deisseroth, AB; Giralt, S; Goodrich, J; Ippoliti, C; Luna, M; Mehra, R; Panina, A; Przepiorka, D; van Besien, K, 1994) |
| "Foscarnet is a pyrophosphate analogue that possesses substantial activity against human cytomegalovirus (HCMV) in patients with CMV retinitis." | 3.69 | In vitro anti-human cytomegalovirus activity of liposome-encapsulated foscarnet. ( Cinatl, J; Doerr, HW; Gümbel, HO; Ohrloff, C; Rabenau, H; Rückert, DG, 1994) |
| "Antiviral activity of L-ascorbic acid-2-phosphate (ASC-2P), a long-acting derivative of L-ascorbic acid, against several human cytomegalovirus (CMV) strains was examined in cultures of human foreskin fibroblasts (HFF) and endothelial cells (EC)." | 3.69 | In vitro inhibition of human cytomegalovirus replication in human foreskin fibroblasts and endothelial cells by ascorbic acid 2-phosphate. ( Chenot, JF; Cinatl, J; Doerr, HW; Encke, A; Gümbel, HO; Rabenau, H; Scholz, M; Weber, B, 1995) |
| "Four human cytomegalovirus (HCMV) isolates from four different AIDS patients treated with both ganciclovir and foscarnet and not responding clinically to antiviral treatment, were studied in order to verify the occurrence of double resistance to both drugs, and to define whether single or multiple HCMV strains could be responsible for the double resistance." | 3.69 | Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. ( Baldanti, F; Barbi, M; Brerra, R; Furione, M; Gerna, G; Percivalle, E; Sarasini, A, 1995) |
| "Three human cytomegalovirus (HCMV) strains (VR4760, VR4955, and VR5120) showing double resistance to ganciclovir (GCV) and foscarnet (PFA) were isolated from three patients with AIDS who underwent multiple sequential courses of therapy with GCV and PFA (A." | 3.69 | Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered f ( Baldanti, F; Biron, KK; Chou, S; Gerna, G; Sarasini, A; Silini, E; Stanat, SC; Underwood, MR, 1996) |
| "To determine the efficacy of combined ganciclovir and foscarnet intravitreal injections in controlling clinically resistant cytomegalovirus retinitis in a 37-year-old man with the acquired immunodeficiency syndrome who refused systemic therapy." | 3.69 | Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. ( Desatnik, HR; Foster, RE; Lowder, CY, 1996) |
| "To determine the prevalence of cytomegalovirus (CMV) isolates resistant to ganciclovir sodium or foscarnet sodium at the time of diagnosis of CMV retinitis, prior to the initiation of therapy." | 3.69 | Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group. ( Bressler, N; Charache, P; Dunn, JP; Enger, C; Forman, M; Jabs, DA, 1996) |
| "Four human cytomegalovirus strains with double resistance to both ganciclovir and foscarnet were recovered from acquired immunodeficiency syndrome (AIDS) patients." | 3.69 | Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. ( Baldanti, F; Barbi, M; Biron, KK; Gerna, G; Lazzarin, A; Sarasini, A; Silini, E, 1995) |
| "In a previous study, we showed that patients undergoing allogeneic hemopoietic stem cell transplantation (HSCT) who had cytomegalovirus (CMV) antigenemia with more than 4 CMV antigen-positive cells/200,000 have a high transplant-related mortality (TRM) rate, despite treatment with ganciclovir or foscarnet." | 3.69 | Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. ( Bacigalupo, A; Bregante, S; Gualandi, F; Isaza, A; Lamparelli, T; Marmont, AM; Occhini, D; Tedone, E; Trespi, G; Van Lint, MT, 1996) |
| "Drug-resistant human cytomegalovirus (HCMV) strains were selected in human embryonic lung (HEL) fibroblasts under pressure of the (S)-3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives of cytosine (HPMPC) and adenine (HPMPA), the 2-phosphonylmethoxyethyl (PME) derivative of 2,6-diaminopurine (PMEDAP), ganciclovir (GCV), acyclovir (ACV), and foscarnet (PFA)." | 3.69 | Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. ( Andrei, G; De Clercq, E; Snoeck, R, 1996) |
| "Cytomegalovirus (CMV) infection is still a problem for organ transplant recipients despite studies that long-term prophylaxis with high dose of acyclovir or ganciclovir given to all organ recipients may limit the consequences of infection and disease." | 3.69 | Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. ( Baruzzo, S; Gotti, E; Moioli, F; Perani, V; Remuzzi, G; Suter, F, 1996) |
| "Antiviral susceptibilities to ganciclovir, foscarnet, and cidofovir and sequencing of UL97 and DNA polymerase were done on 23 cytomegalovirus (CMV) isolates from 10 immunocompromised persons with end-organ CMV disease who were treated with ganciclovir alone or ganciclovir followed by foscarnet." | 3.69 | Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. ( Balfour, HH; Boivin, G; Chou, S; Erice, A; Gil-Roda, C; Hanson, MN; Pérez, JL; Sannerud, KJ, 1997) |
| "In a human immunodeficiency virus-infected subject, cytomegalovirus (CMV) isolated 9 months after the patient began oral ganciclovir prophylaxis was resistant to ganciclovir and cidofovir and contained mutations in both UL97 and Pol coding regions." | 3.69 | Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. ( Chou, S; Drew, WL; Follansbee, SE; Guentzel, S; Lalezari, JP; Marousek, G; Miner, RC; Poscher, ME, 1997) |
| "Antiviral susceptibility testing-flow cytometric analysis (AST-FCA), an application of flow cytometry in conjunction with cell culture, was developed to identify susceptibility of cytomegalovirus (CMV) isolates to the antiviral drugs ganciclovir (GCV) and foscarnet (PFA)." | 3.69 | Antiviral susceptibility testing-flow cytometric analysis (AST-FCA) for the detection of cytomegalovirus drug resistance. ( Biondo, FX; Kaplan, MH; Lipson, SM; Shepp, DH; Soni, M; Sun, T, 1997) |
| "In order to assess the value of quantitative measurement of cytomegalovirus (CMV) antigenaemia as a marker for the guidance of antiviral chemotherapy in the AIDS setting, 33 patients with CMV complications and showing at least 20 pp65-positive polymorphonuclear leucocytes per 2 x 10(5) cells, received either ganciclovir or foscarnet as induction and maintenance therapy." | 3.69 | Quantitative cytomegalovirus (CMV) antigenaemia during antiviral treatment of AIDS-related CMV disease. ( Chiodo, F; Coronado, OV; Dal Monte, P; Lazzarotto, T; Manfredi, R; Mastroianni, A; Spezzacatena, P, 1997) |
| " The patient also suffered from recurrent cytomegalovirus (CMV) viremia, treated with foscarnet and ganciclovir." | 3.69 | Successful allogeneic bone marrow transplantation in a 2.5-year-old boy with ongoing cytomegalovirus viremia and severe aplastic anemia after orthotopic liver transplantation for non-A, non-B, non-C hepatitis. ( Ericzon, BG; Hägglund, H; Ringdén, O; Sparrelid, E; Winiarski, J, 1997) |
| " Cytomegalovirus prophylaxis consisted of acyclovir for SIBs and foscarnet for MUDs." | 3.69 | Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. ( Bacigalupo, A; Barbanti, M; Corvo, R; Delfino, L; Ferrara, GB; Ficai, G; Frassoni, F; Ghinatti, C; Gualandi, F; Lamparelli, T; Morabito, A; Occhini, D; Pozzi, S; Sacchi, N; Van Lint, MT; Vitale, V; Zikos, P, 1997) |
| "Cytomegalovirus (CMV) retinitis, a sight-threatening infection common in AIDS patients, can be treated systemically with intravenous ganciclovir, intravenous foscarnet, or oral ganciclovir." | 3.69 | Intraocular therapy for cytomegalovirus retinitis. ( Palestine, AG, 1996) |
| "While progress has been made in managing cytomegalovirus (CMV) infections, researchers are debating the problem of drug resistance and the significance of ganciclovir resistance research data." | 3.69 | CMV resistance: "more complicated than we thought". ( Mascolini, M, 1996) |
| "The human cytomegalovirus (HCMV) gene UL97 product was shown to play an important role in phosphorylation of ganciclovir (GCV) in HCMV-infected cells." | 3.68 | Rapid detection of cytomegalovirus strains resistant to ganciclovir through mutations within the gene UL97. ( Alain, S; Mazeron, MC; Morinet, F; Pépin, JM; Raskine, L; Sanson-Le Pors, MJ, 1993) |
| "Clinical isolates of human cytomegalovirus (HCMV) were screened for susceptibility to ganciclovir by plaque-reduction assay and in situ ELISA." | 3.68 | A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. ( Lurain, NS; Tatarowicz, WA; Thompson, KD, 1992) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 3.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Investigations of mutants of human cytomegalovirus (CMV) that are resistant to foscarnet could shed light on mechanisms of selective drug action and features of drug resistance that may be clinically important." | 3.68 | Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. ( Coen, DM; Sullivan, V, 1991) |
| "The antiviral effect of ganciclovir and foscarnet encapsulated in liposomes was studied against cytomegalovirus in human embryonic lung fibroblast cells." | 3.68 | Increased efficacy of ganciclovir and foscarnet inhibition of cytomegalovirus replication in vitro by encapsulation in liposomes. ( Bakker-Woudenberg, IA; Lokerse, AF; ten Kate, M, 1990) |
| "Ganciclovir and foscarnet possess substantial activity against cytomegalovirus." | 3.68 | Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. ( Lane, HC; Manischewitz, JF; Quinnan, GV; Wittek, AE, 1990) |
| "Eight patients, 7 renal and 1 combined renal and pancreas allograft recipients with generalized cytomegalovirus (CMV) infection were treated with continuous intravenous foscarnet infusion (0." | 3.67 | Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants. ( Akesson-Johansson, A; Andersson, J; Brattström, C, 1989) |
| "Results presented here show that when cytomegalovirus (strain Colburn)-infected cells are treated with the DNA synthesis inhibitor hydroxyurea or phosphonoformate, one type of intranuclear capsid accumulates." | 3.67 | Primate cytomegalovirus assembly: evidence that DNA packaging occurs subsequent to B capsid assembly. ( Gibson, W; Irmiere, A; Lee, JY, 1988) |
| "The antiviral activity of trifluorothymidine (TFT) singly and in combination with other antiviral agents against human cytomegalovirus (HCMV) was evaluated by using an infectious center plaque reduction assay." | 3.66 | Inhibition of human cytomegalovirus by trifluorothymidine. ( Kelley, E; Spector, SA; Tyndall, M, 1983) |
| "ACTG 266 was designed as a randomized study to evaluate two doses of the human monoclonal antibody directed against CMV gH (MSL-109) versus placebo, each in combination with standard antiviral therapy for the treatment of newly diagnosed Cytomegalovirus (CMV) retinitis in AIDS patients." | 2.71 | A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus re ( Alston, B; Asmuth, DM; Aweeka, F; Borucki, MJ; Caliendo, A; Gnann, J; Hirsch, MS; Hubbard, L; Nadler, PI; Nevin, TT; Nokta, M; Owens, S; Pollard, RB; Sattler, F; Spritzler, J; Waterman, K, 2004) |
| " These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms." | 2.66 | Antiviral chemotherapy and chemoprophylaxis. ( Dolin, R, 1985) |
| "Although cytomegalovirus is one of the most prevalent viral pathogens on the globe, in immunocompetent individuals infected with cytomegalovirus usually no specific antiviral therapy is required." | 2.61 | [Current treatment modalities of immunocompromised patients with cytomegalovirus infection. II. Therapeutic options and management strategies]. ( Sinkó, J, 2019) |
| "Foscarnet is a reasonable first line anti CMV agent in this setting." | 2.46 | CMV-related thrombocytopenia treated with foscarnet: a case series and review of the literature. ( Chajek-Shaul, T; Hershcovici, T; Koslowsky, B; Wolf, D; Yaari, S, 2010) |
| " The emergence of drug resistance may be reduced by optimization of host immunity, use of potent antiviral drug regimens, and adherence to dosing regimens that adequately suppress viral replication." | 2.41 | Cytomegalovirus drug resistance and clinical implications. ( Chou, SW, 2001) |
| "Although mortality was high in this population, foscarnet use, with proper precautions, was generally safe and significant renal dysfunction was lower than previously reported in other sources, even with extended use." | 1.48 | Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study. ( Allen, A; Ison, MG; Lacloche, L; Pierce, B; Richardson, CL, 2018) |
| "Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking." | 1.43 | Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. ( Ariza-Heredia, E; Chemaly, RF; Doan, V; El Chaer, F; Jan, A; Mori, N; Oliver, N; Shah, D; Tayar, J; Tverdek, F; Wang, E, 2016) |
| " The selected compounds differed by the slopes of their dose-response curve: compounds with a slope of 1 (GCV) representing one target or noncooperativity and compounds with high slopes indicating positive cooperativity." | 1.40 | In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action. ( Arav-Boger, R; Cai, H; Forman, M; He, R; Kapoor, A; Posner, GH; Venkatadri, R, 2014) |
| "A severely T-cell-depleted patient with chronic lymphocytic leukemia developed CMV pneumonia and high plasma viral loads that were poorly responsive to antiviral therapy." | 1.40 | Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. ( Chou, S; Ercolani, RJ; Lefterova, MI; Pinsky, BA; Sahoo, MK; Strasfeld, LM, 2014) |
| "Cytomegalovirus retinitis is an opportunistic infection found in AIDS patients as well as in bone marrow and solid organ transplant recipients being treated with systemic immunosuppressive drugs." | 1.39 | A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma in a patient with systemic non-Hodgkin's lymphoma. ( Brichová, M; Dvořák, J; Heissigerová, J; Kalvodová, B; Ríhová, E; Svozílková, P, 2013) |
| "Foscarnet was discontinued because of concern about its potential central nervous system toxicity." | 1.31 | Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient. ( Balfour, HH; Clark, HB; Holman, CJ; Julin, JE; Krivit, W; van Burik, JH; Webb, C, 2002) |
| "Patients with multiple myeloma and lymphoma, possibly owing to a combination of disease-related characteristics and prior immunosuppressive treatment, had high rates of CMV reactivation and may require more frequent diagnostic evaluation and prompt therapeutic intervention." | 1.31 | Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. ( Bolaños-Meade, J; Buddharaju, LN; Chen, T; Cottler-Fox, M; Cross, A; Fassas, AB; Lovchik, JC; Rapoport, A; Tricot, G, 2001) |
| "Foscarnet was not liberated on incubation of n-tetradecyl 6-O-carboxyphosphonyl-alpha-D-glucopyranoside with rat liver or intestine homogenate, neither could the neoglycolipid conjugate nor foscarnet be detected in rat plasma following oral administration." | 1.30 | Neoglycolipid conjugates of foscarnet with enhanced antiviral activity in cells infected with human cytomegalovirus and herpes simplex virus type 1. ( Dypbukt, J; Ljungdahl-Ståhle, E; Maloisel, JL; Pring, BG; Tidén, AK, 1999) |
| " The ability of ISIS 2922 to inhibit replication of HCMV when used in combination with other antiviral agents approved for treatment of HCMV disease was investigated using a 96-well immunoassay." | 1.29 | Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. ( Anderson, KP; Azad, RF; Brown-Driver, V; Buckheit, RW, 1995) |
| "Effective diagnosis and treatment of cytomegalovirus infection of the nervous system in AIDS patients has been limited by a lack of sensitive diagnostic measures." | 1.29 | Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS. ( Cohen, BA, 1996) |
| "A patient with Hodgkin's disease presented with an atypical retinitis, vasculitis, and a serous macular detachment." | 1.29 | Cytomegalovirus retinitis associated with Hodgkin's disease. ( Jaffe, GJ; Nasir, MA, 1996) |
| "Fifty AIDS patients were investigated for human cytomegalovirus (HCMV) viraemia when potentially HCMV-related clinical symptoms or syndromes were observed." | 1.28 | Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia. ( Gaballo, A; Gerna, G; Milanesi, G; Parea, M; Percivalle, E; Zavattoni, M; Zipeto, D, 1991) |
| "A concomitant treatment of cytomegalovirus infections, such as cytomegalovirus retinitis, with phosphonoformate in patients with acquired immunodeficiency syndrome receiving 3'-azido-3'-deoxythymidine may be appropriate, and this combination may also be useful in controlling human immunodeficiency virus infection." | 1.28 | Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. ( Eriksson, BF; Schinazi, RF, 1989) |
| " The antiCMV activity of acyclovir in combination with human fibroblast interferon (IFN-beta), phosphonoformic acid (PFA), or trifluorothymidine (TFT) was therefore evaluated." | 1.26 | Effects of acyclovir combined with other antiviral agents on human cytomegalovirus. ( Kelley, E; Spector, SA; Tyndall, M, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (6.23) | 18.7374 |
| 1990's | 110 (38.06) | 18.2507 |
| 2000's | 87 (30.10) | 29.6817 |
| 2010's | 61 (21.11) | 24.3611 |
| 2020's | 13 (4.50) | 2.80 |
| Authors | Studies |
|---|---|
| Devivar, RV | 1 |
| Kawashima, E | 1 |
| Revankar, GR | 1 |
| Breitenbach, JM | 1 |
| Kreske, ED | 1 |
| Drach, JC | 6 |
| Townsend, LB | 5 |
| Zou, R | 2 |
| Migawa, MT | 1 |
| Girardet, JL | 1 |
| Walker, JA | 1 |
| Koszalka, GW | 1 |
| Chamberlain, SD | 1 |
| Chen, JJ | 1 |
| Wei, Y | 1 |
| Jeong, LS | 1 |
| Kim, HO | 1 |
| Moon, HR | 1 |
| Hong, JH | 1 |
| Yoo, SJ | 1 |
| Choi, WJ | 1 |
| Chun, MW | 1 |
| Lee, CK | 1 |
| McGuigan, C | 1 |
| Pathirana, RN | 1 |
| Snoeck, R | 8 |
| Andrei, G | 6 |
| De Clercq, E | 6 |
| Balzarini, J | 4 |
| Schnute, ME | 3 |
| Cudahy, MM | 3 |
| Brideau, RJ | 4 |
| Homa, FL | 1 |
| Hopkins, TA | 5 |
| Knechtel, ML | 5 |
| Oien, NL | 5 |
| Pitts, TW | 1 |
| Poorman, RA | 1 |
| Wathen, MW | 5 |
| Wieber, JL | 5 |
| Scott, GM | 2 |
| Weinberg, A | 7 |
| Rawlinson, WD | 2 |
| Chou, S | 23 |
| Anderson, DJ | 1 |
| Ciske, FL | 1 |
| Collier, SA | 2 |
| Eggen, M | 1 |
| Genin, MJ | 1 |
| Judge, TM | 1 |
| Kim, EJ | 1 |
| Nair, SK | 2 |
| Nieman, JA | 2 |
| Scott, A | 2 |
| Tanis, SP | 1 |
| Vaillancourt, VA | 1 |
| Larsen, SD | 1 |
| Zhang, Z | 2 |
| DiPaolo, BA | 1 |
| Manninen, PR | 1 |
| Rohrer, DC | 1 |
| Hageman, MJ | 1 |
| Rush, BD | 1 |
| Schwende, FJ | 1 |
| Stefanski, KJ | 1 |
| Wilkinson, KF | 1 |
| Zamora, KM | 1 |
| Marousek, GI | 3 |
| Van Wechel, LC | 1 |
| Li, S | 4 |
| Sackett, RS | 1 |
| Stephan, ML | 1 |
| de Castro, S | 2 |
| Peromingo, MT | 1 |
| Naesens, L | 3 |
| Velázquez, S | 2 |
| Camarasa, MJ | 2 |
| Schott, H | 1 |
| Hamprecht, K | 5 |
| Schott, S | 1 |
| Schott, TC | 1 |
| Schwendener, RA | 1 |
| García-Aparicio, C | 1 |
| Heasley, SE | 1 |
| Schultz, BL | 1 |
| Zerth, HM | 1 |
| Nugent, RA | 1 |
| Chen, K | 1 |
| Stephanski, KJ | 1 |
| Avery, RK | 4 |
| Alain, S | 9 |
| Alexander, BD | 1 |
| Blumberg, EA | 1 |
| Chemaly, RF | 2 |
| Cordonnier, C | 2 |
| Duarte, RF | 1 |
| Florescu, DF | 1 |
| Kamar, N | 1 |
| Kumar, D | 1 |
| Maertens, J | 1 |
| Marty, FM | 1 |
| Papanicolaou, GA | 1 |
| Silveira, FP | 1 |
| Witzke, O | 1 |
| Wu, J | 1 |
| Sundberg, AK | 1 |
| Fournier, M | 1 |
| Khorenko, M | 1 |
| Rand, U | 1 |
| Cicin-Sain, L | 1 |
| Feldmann, C | 1 |
| Jung, JY | 1 |
| Nho, D | 1 |
| Cho, SY | 1 |
| Lee, DG | 1 |
| Choi, SM | 1 |
| Kim, HJ | 2 |
| Kim, M | 1 |
| Oh, EJ | 1 |
| Qin, A | 1 |
| Chen, S | 1 |
| Li, Q | 1 |
| Huang, X | 1 |
| Xia, L | 1 |
| Lin, Y | 1 |
| Shen, A | 1 |
| Xiang, AP | 1 |
| Zhang, L | 1 |
| Demin, MV | 2 |
| Tikhomirov, DS | 2 |
| Tupoleva, TA | 2 |
| Filatov, FP | 2 |
| Razonable, RR | 2 |
| Kleiboeker, SB | 1 |
| Leung, PYM | 1 |
| Tran, T | 1 |
| Testro, A | 1 |
| Paizis, K | 1 |
| Kwong, J | 1 |
| Whitlam, JB | 1 |
| Spinner, ML | 1 |
| Lam, SW | 1 |
| Koval, CE | 1 |
| Athans, V | 1 |
| Hakki, M | 2 |
| Zarrouk, K | 2 |
| Pham, VD | 2 |
| Piret, J | 4 |
| Shi, R | 2 |
| Boivin, G | 10 |
| Baldo, F | 1 |
| Suárez, NM | 1 |
| Davison, AJ | 1 |
| Zanon, D | 1 |
| Barbi, E | 1 |
| Maximova, N | 1 |
| Miyao, K | 1 |
| Terakura, S | 1 |
| Ozawa, Y | 1 |
| Sawa, M | 1 |
| Kohno, A | 1 |
| Kasahara, S | 1 |
| Iida, H | 1 |
| Ino, K | 1 |
| Kusumoto, S | 1 |
| Kasai, M | 1 |
| Takami, A | 1 |
| Kurahashi, S | 1 |
| Kajiguchi, T | 1 |
| Morishita, T | 1 |
| Nishida, T | 1 |
| Murata, M | 1 |
| Zhu, X | 1 |
| Goyette, N | 3 |
| Rho, E | 1 |
| Näf, B | 1 |
| Müller, TF | 1 |
| Wüthrich, RP | 1 |
| Schachter, T | 1 |
| von Moos, S | 1 |
| Bruminhent, J | 1 |
| Rotjanapan, P | 1 |
| Watcharananan, SP | 1 |
| Echenique, IA | 1 |
| Beltran, D | 1 |
| Ramirez-Ruiz, L | 1 |
| Najafian, N | 1 |
| Agrawal, N | 1 |
| Pushkarevskaya, A | 1 |
| Bidier, M | 1 |
| Hartmann, M | 1 |
| Enk, A | 1 |
| Hadaschik, E | 1 |
| Pierce, B | 1 |
| Richardson, CL | 1 |
| Lacloche, L | 1 |
| Allen, A | 1 |
| Ison, MG | 2 |
| Cintra-Cabrera, M | 1 |
| Suárez-Benjumea, A | 1 |
| Bernal-Blanco, G | 1 |
| González-Roncero, FM | 1 |
| Toapanta-Gaibor, NG | 1 |
| Súñer-Poblet, M | 1 |
| Pérez-Valdivia, MÁ | 1 |
| Fernández-Cuenca, F | 1 |
| Gentil-Govantes, MÁ | 1 |
| Rocha-Castilla, JL | 1 |
| Vora, SB | 1 |
| Brothers, AW | 1 |
| Waghmare, A | 1 |
| Englund, JA | 1 |
| Metafuni, E | 1 |
| Chiusolo, P | 1 |
| Sica, S | 1 |
| Laurenti, L | 1 |
| Bregante, S | 3 |
| Van Lint, MT | 5 |
| Dominietto, A | 1 |
| Angelucci, E | 1 |
| Bacigalupo, A | 5 |
| Meesing, A | 1 |
| Rothman, AL | 1 |
| Walter, SD | 1 |
| O'Brien, MS | 1 |
| Markovich, KC | 1 |
| Selleseth, D | 1 |
| DeVita, AV | 1 |
| Sethna, P | 1 |
| Gentry, BG | 1 |
| Nawashiro, Y | 1 |
| Shiraki, K | 2 |
| Yamamoto, S | 2 |
| Takizawa, K | 1 |
| Sasada, Y | 1 |
| Suehiro, M | 1 |
| Miura, K | 1 |
| Hattori, M | 1 |
| Daikoku, T | 1 |
| Hisano, M | 1 |
| Danziger-Isakov, L | 1 |
| Englund, J | 1 |
| Green, M | 1 |
| Posfay-Barbe, KM | 1 |
| Zerr, DM | 1 |
| Sinkó, J | 1 |
| Gupta, S | 1 |
| Vemulakonda, GA | 1 |
| Suhler, EB | 1 |
| Yeh, S | 2 |
| Albini, TA | 1 |
| Mandelcorn, E | 1 |
| Flaxel, CJ | 2 |
| Or, C | 1 |
| Press, N | 1 |
| Forooghian, F | 2 |
| Schneider, EW | 1 |
| Elner, SG | 1 |
| van Kuijk, FJ | 1 |
| Goldberg, N | 1 |
| Lieberman, RM | 1 |
| Eliott, D | 1 |
| Johnson, MW | 1 |
| James, SH | 1 |
| Price, NB | 1 |
| Hartline, CB | 1 |
| Lanier, ER | 2 |
| Prichard, MN | 2 |
| Sakamoto, K | 1 |
| Nakasone, H | 1 |
| Wada, H | 1 |
| Yamasaki, R | 1 |
| Ishihara, Y | 1 |
| Kawamura, K | 1 |
| Ashizawa, M | 1 |
| Sato, M | 1 |
| Terasako-Saito, K | 1 |
| Machishima, T | 1 |
| Kimura, S | 1 |
| Kikuchi, M | 1 |
| Kako, S | 2 |
| Kanda, J | 1 |
| Yamazaki, R | 1 |
| Tanihara, A | 1 |
| Nishida, J | 1 |
| Kanda, Y | 3 |
| Fischer, L | 2 |
| Laib Sampaio, K | 1 |
| Jahn, G | 5 |
| Göhring, K | 2 |
| Cai, H | 1 |
| Kapoor, A | 1 |
| He, R | 1 |
| Venkatadri, R | 1 |
| Forman, M | 3 |
| Posner, GH | 1 |
| Arav-Boger, R | 1 |
| Verkaik, NJ | 1 |
| Hoek, RA | 1 |
| van Bergeijk, H | 1 |
| van Hal, PT | 1 |
| Schipper, ME | 1 |
| Pas, SD | 1 |
| Beersma, MF | 1 |
| Boucher, CA | 1 |
| Jedema, I | 1 |
| Falkenburg, F | 1 |
| Hoogsteden, HC | 1 |
| van den Blink, B | 1 |
| Murk, JL | 1 |
| Komazin-Meredith, G | 1 |
| Williams, JD | 1 |
| Bowlin, TL | 2 |
| Gregg, K | 1 |
| Kaul, DR | 1 |
| Russo, E | 1 |
| Gaglianone, N | 1 |
| Baldassari, S | 1 |
| Parodi, B | 1 |
| Cafaggi, S | 1 |
| Zibana, C | 1 |
| Donalisio, M | 1 |
| Cagno, V | 1 |
| Lembo, D | 1 |
| Caviglioli, G | 1 |
| Ercolani, RJ | 2 |
| Sahoo, MK | 1 |
| Lefterova, MI | 1 |
| Strasfeld, LM | 1 |
| Pinsky, BA | 1 |
| Deback, C | 1 |
| Burrel, S | 2 |
| Varnous, S | 1 |
| Carcelain, G | 1 |
| Conan, F | 1 |
| Aït-Arkoub, Z | 1 |
| Autran, B | 1 |
| Gandjbakhch, I | 1 |
| Agut, H | 3 |
| Boutolleau, D | 3 |
| Vishnevskia-Dai, V | 1 |
| Shapira, Y | 1 |
| Rahav, G | 1 |
| Shimoni, A | 1 |
| Somech, R | 1 |
| Moisseiev, J | 1 |
| Eckenroth, BE | 1 |
| Drouot, E | 1 |
| Götte, M | 4 |
| Andouard, D | 1 |
| Mazeron, MC | 7 |
| Ligat, G | 1 |
| Couvreux, A | 1 |
| Pouteil-Noble, C | 1 |
| Cahen, R | 1 |
| Yasdanpanah, Y | 1 |
| Deering, M | 1 |
| Viget, N | 1 |
| Hantz, S | 1 |
| Young, PG | 1 |
| Rubin, J | 1 |
| Angarone, M | 1 |
| Flaherty, J | 1 |
| Penugonda, S | 1 |
| Stosor, V | 1 |
| Imrich, E | 1 |
| Sampaio, KL | 1 |
| Hofmann, J | 1 |
| Garrigue, I | 1 |
| Moulinas, R | 1 |
| Recordon-Pinson, P | 1 |
| Delacour, ML | 1 |
| Essig, M | 1 |
| Kaminski, H | 1 |
| Rerolle, JP | 1 |
| Merville, P | 1 |
| Fleury, H | 1 |
| Kang, GW | 1 |
| Hong, HL | 1 |
| Lee, IH | 1 |
| Ahn, KS | 1 |
| Kim, JD | 1 |
| Choi, DL | 1 |
| Mihm, J | 1 |
| Leyking, S | 1 |
| Dirks, J | 1 |
| Smola, S | 1 |
| Fliser, D | 1 |
| Sester, U | 1 |
| Sester, M | 1 |
| Wilkens, H | 1 |
| Rissland, J | 1 |
| El Chaer, F | 1 |
| Mori, N | 1 |
| Shah, D | 1 |
| Oliver, N | 1 |
| Wang, E | 1 |
| Jan, A | 1 |
| Doan, V | 1 |
| Tverdek, F | 1 |
| Tayar, J | 1 |
| Ariza-Heredia, E | 1 |
| Nomura, JH | 1 |
| Eichhorn, K | 1 |
| Cao, TM | 1 |
| Sahebi, F | 1 |
| Boss, JD | 1 |
| Rosenberg, K | 1 |
| Shah, R | 1 |
| Oshima, K | 1 |
| Asano-Mori, Y | 1 |
| Watanabe, T | 1 |
| Motokura, T | 1 |
| Chiba, S | 2 |
| Kurokawa, M | 1 |
| Péter, A | 1 |
| Telkes, G | 1 |
| Varga, M | 1 |
| Járay, J | 1 |
| Wang, H | 1 |
| Zhu, L | 1 |
| Xue, M | 1 |
| Liu, J | 1 |
| Guo, Z | 1 |
| Rothova, A | 1 |
| de Weerdt, O | 1 |
| Sola, E | 1 |
| Vega, E | 1 |
| Gutiérrez, C | 1 |
| López, V | 1 |
| Cabello, M | 1 |
| Burgos, D | 1 |
| González Molina, M | 1 |
| Siles, J | 1 |
| Travi, G | 1 |
| Pergam, SA | 1 |
| Xie, H | 2 |
| Boeckh, MJ | 1 |
| Tchesnokov, EP | 3 |
| Obikhod, A | 1 |
| Schinazi, RF | 2 |
| Jabs, DA | 5 |
| Martin, BK | 2 |
| Forman, MS | 3 |
| Meghpara, B | 1 |
| Sulkowski, G | 1 |
| Kesen, MR | 1 |
| Tessler, HH | 1 |
| Goldstein, DA | 1 |
| Martin, M | 1 |
| Azzi, A | 2 |
| Lin, SX | 2 |
| Yaari, S | 1 |
| Koslowsky, B | 1 |
| Wolf, D | 1 |
| Chajek-Shaul, T | 1 |
| Hershcovici, T | 1 |
| Xia, CS | 1 |
| Lurain, NS | 7 |
| Kern, ER | 1 |
| Zahn, KE | 1 |
| Doublié, S | 1 |
| Myhre, HA | 1 |
| Haug Dorenberg, D | 1 |
| Kristiansen, KI | 1 |
| Rollag, H | 1 |
| Leivestad, T | 1 |
| Asberg, A | 1 |
| Hartmann, A | 1 |
| Gilbert, C | 2 |
| Marousek, G | 4 |
| Fahle, G | 1 |
| Faia, LJ | 1 |
| Weichel, ED | 1 |
| Stout, JT | 1 |
| Lauer, AK | 1 |
| Sen, HN | 1 |
| Nussenblatt, RB | 1 |
| Moss, HB | 1 |
| Chavala, S | 1 |
| Say, E | 1 |
| Miller, MB | 1 |
| Canestri, A | 1 |
| Wirden, M | 1 |
| Seang, S | 1 |
| Clavel-Osorio, C | 1 |
| Marcelin, AG | 1 |
| Katlama, C | 3 |
| Goldsmith, PM | 1 |
| Husain, MM | 1 |
| Carmichael, A | 1 |
| Zhang, H | 1 |
| Middleton, SJ | 1 |
| Cunha-Bang, Cd | 1 |
| Kirkby, N | 1 |
| Sønderholm, M | 1 |
| Sørensen, SS | 1 |
| Sengeløv, H | 1 |
| Iversen, M | 1 |
| Rasmussen, A | 1 |
| Gustafsson, F | 1 |
| Frederiksen, CM | 1 |
| Kjaer, J | 1 |
| Lepri, AC | 1 |
| Lundgren, JD | 1 |
| Svozílková, P | 1 |
| Heissigerová, J | 1 |
| Brichová, M | 1 |
| Kalvodová, B | 1 |
| Dvořák, J | 1 |
| Ríhová, E | 1 |
| Zaia, JA | 1 |
| Baldanti, F | 12 |
| Sarasini, A | 8 |
| Zemlicka, J | 1 |
| Gerna, G | 13 |
| Isada, CM | 1 |
| Yen-Lieberman, B | 2 |
| Schilz, R | 1 |
| Kohn, D | 1 |
| Longworth, DL | 1 |
| Taege, AJ | 2 |
| Mossad, SB | 1 |
| Maurer, J | 1 |
| Flechner, SM | 1 |
| Mawhorter, SD | 1 |
| Braun, W | 1 |
| Gordon, SM | 2 |
| Schmitt, SK | 1 |
| Goldman, M | 1 |
| Long, J | 1 |
| Haug, M | 1 |
| Julin, JE | 1 |
| van Burik, JH | 1 |
| Krivit, W | 1 |
| Webb, C | 1 |
| Holman, CJ | 1 |
| Clark, HB | 1 |
| Balfour, HH | 3 |
| Crumpacker, C | 2 |
| Mousavi-Jazi, M | 4 |
| Schloss, L | 3 |
| Wahren, B | 9 |
| Brytting, M | 4 |
| van der Strate, BW | 1 |
| De Boer, FM | 1 |
| Bakker, HI | 1 |
| Meijer, DK | 1 |
| Molema, G | 1 |
| Harmsen, MC | 1 |
| Ducancelle, A | 4 |
| Belloc, S | 1 |
| Scieux, C | 1 |
| Malphettes, M | 1 |
| Petit, F | 4 |
| Brouet, JC | 1 |
| Sanson Le Pors, MJ | 2 |
| Mattes, FM | 1 |
| Hainsworth, EG | 1 |
| Geretti, AM | 1 |
| Nebbia, G | 1 |
| Prentice, G | 1 |
| Potter, M | 1 |
| Burroughs, AK | 1 |
| Sweny, P | 1 |
| Hassan-Walker, AF | 1 |
| Okwuadi, S | 1 |
| Sabin, C | 1 |
| Amooty, G | 1 |
| Brown, VS | 1 |
| Grace, SC | 1 |
| Emery, VC | 3 |
| Griffiths, PD | 2 |
| Fryer, JF | 1 |
| Clark, DA | 1 |
| Lurain, N | 2 |
| Nash, PJ | 1 |
| Tang, WH | 1 |
| Starling, RC | 1 |
| Yamani, MH | 1 |
| Nigro, G | 1 |
| Sali, E | 1 |
| Anceschi, MM | 1 |
| Mazzocco, M | 1 |
| Maranghi, L | 1 |
| Clerico, A | 1 |
| Castello, MA | 1 |
| Monno, R | 1 |
| Rendina, M | 1 |
| Ceci, G | 1 |
| Rizzo, C | 1 |
| Luzzi, I | 1 |
| Francavilla, A | 1 |
| Rizzo, G | 1 |
| Ierardi, E | 1 |
| Borucki, MJ | 1 |
| Spritzler, J | 1 |
| Asmuth, DM | 1 |
| Gnann, J | 1 |
| Hirsch, MS | 1 |
| Nokta, M | 3 |
| Aweeka, F | 1 |
| Nadler, PI | 2 |
| Sattler, F | 1 |
| Alston, B | 1 |
| Nevin, TT | 1 |
| Owens, S | 1 |
| Waterman, K | 1 |
| Hubbard, L | 2 |
| Caliendo, A | 1 |
| Pollard, RB | 2 |
| Springer, KL | 1 |
| Giller, RH | 1 |
| Quinones, R | 1 |
| Shira, JE | 1 |
| Gravisse, J | 1 |
| Fillet, AM | 3 |
| Pors, MJ | 1 |
| Tanaka-Taya, K | 3 |
| Drew, WL | 12 |
| de Schryver, I | 1 |
| Rozenberg, F | 1 |
| Cassoux, N | 1 |
| Michelson, S | 1 |
| Kestelyn, P | 1 |
| Lehoang, P | 1 |
| Davis, JL | 1 |
| Bodaghi, B | 1 |
| Murayama, T | 1 |
| Stephens, CE | 1 |
| Loregian, A | 1 |
| De Bolle, L | 1 |
| Sowell, JW | 1 |
| Champier, G | 1 |
| Le Pors, MJ | 1 |
| Miner, RC | 5 |
| Narimatsu, H | 2 |
| Kami, M | 2 |
| Kato, D | 1 |
| Matsumura, T | 2 |
| Murashige, N | 2 |
| Kusumi, E | 2 |
| Yuji, K | 2 |
| Hori, A | 2 |
| Shibata, T | 1 |
| Masuoka, K | 2 |
| Wake, A | 2 |
| Miyakoshi, S | 2 |
| Morinaga, S | 1 |
| Taniguchi, S | 2 |
| Tanaka, Y | 1 |
| Eizuru, Y | 1 |
| Fica, A | 1 |
| Cervera, C | 1 |
| Pérez, N | 1 |
| Marcos, MA | 1 |
| Ramírez, J | 1 |
| Linares, L | 1 |
| Soto, G | 1 |
| Navasa, M | 1 |
| Cofan, F | 1 |
| Ricart, MJ | 1 |
| Pérez-Villa, F | 1 |
| Pumarola, T | 1 |
| Moreno, A | 1 |
| Iwasenko, JM | 1 |
| Ziegler, JB | 1 |
| Rodriguez, J | 1 |
| Casper, K | 1 |
| Smallwood, G | 1 |
| Stieber, A | 1 |
| Fasola, C | 1 |
| Lehneman, J | 1 |
| Heffron, T | 1 |
| Bonnafous, P | 1 |
| Petrella, S | 1 |
| Gautheret-Dejean, A | 1 |
| Sougakoff, W | 1 |
| Reddy, AJ | 1 |
| Zaas, AK | 1 |
| Hanson, KE | 1 |
| Palmer, SM | 1 |
| Shapira, MY | 1 |
| Resnick, IB | 1 |
| Neumann, AU | 1 |
| Stamminger, T | 1 |
| Caplan, O | 1 |
| Saleh, N | 1 |
| Efferth, T | 1 |
| Marschall, M | 1 |
| Wolf, DG | 2 |
| Robèrt, KH | 1 |
| Nordlund, S | 1 |
| Spector, SA | 2 |
| Tyndall, M | 2 |
| Kelley, E | 2 |
| Oberg, B | 3 |
| Wagstaff, AJ | 1 |
| Bryson, HM | 1 |
| McCann, JD | 1 |
| Margolis, TP | 1 |
| Wong, MG | 1 |
| Kuppermann, BD | 3 |
| Luckie, AP | 1 |
| Schwartz, DM | 1 |
| Irvine, AR | 1 |
| Ai, E | 1 |
| Blanshard, C | 1 |
| Benhamou, Y | 1 |
| Dohin, E | 1 |
| Lernestedt, JO | 2 |
| Gazzard, BG | 1 |
| Dunn, JP | 3 |
| MacCumber, MW | 1 |
| Charache, P | 2 |
| Apuzzo, L | 1 |
| Roedel, C | 1 |
| Grob, R | 1 |
| Ruef, C | 1 |
| Percivalle, E | 8 |
| Zavattoni, M | 3 |
| Revello, MG | 6 |
| Le Goff, C | 1 |
| Hurault de Ligny, B | 1 |
| Freymuth, F | 2 |
| Cardineau, E | 1 |
| Lobbedez, T | 1 |
| Ryckelynck, JP | 1 |
| Tedone, E | 3 |
| Moro, F | 1 |
| Sanna, MA | 1 |
| Longren, M | 1 |
| Trespi, G | 2 |
| Frassoni, F | 2 |
| Occhini, D | 4 |
| Gualandi, F | 4 |
| Tolpin, MD | 1 |
| Roullet, E | 1 |
| Assuerus, V | 1 |
| Gozlan, J | 2 |
| Ropert, A | 1 |
| Saïd, G | 1 |
| Baudrimont, M | 1 |
| el Amrani, M | 1 |
| Jacomet, C | 1 |
| Duvivier, C | 1 |
| Gonzales-Canali, G | 1 |
| Przepiorka, D | 1 |
| Ippoliti, C | 1 |
| Panina, A | 1 |
| Goodrich, J | 1 |
| Giralt, S | 1 |
| van Besien, K | 1 |
| Mehra, R | 1 |
| Deisseroth, AB | 1 |
| Andersson, B | 1 |
| Luna, M | 1 |
| Domingo, P | 1 |
| Puig, M | 1 |
| Iranzo, A | 1 |
| Lopez-Contreras, J | 1 |
| Ris, J | 1 |
| Furione, M | 3 |
| Zipeto, D | 2 |
| Zella, D | 2 |
| Gümbel, HO | 2 |
| Rückert, DG | 1 |
| Cinatl, J | 3 |
| Rabenau, H | 2 |
| Doerr, HW | 2 |
| Ohrloff, C | 1 |
| Pépin, JM | 2 |
| Morinet, F | 1 |
| Raskine, L | 1 |
| Sanson-Le Pors, MJ | 1 |
| Leport, C | 3 |
| Puget, S | 1 |
| Levy, S | 1 |
| Perronne, C | 1 |
| Brun-Vezinet, F | 2 |
| Vildé, JL | 2 |
| Petitjean, J | 1 |
| Eugene-Ruelland, G | 1 |
| Daon, F | 1 |
| Galateau, F | 1 |
| Snydman, DR | 1 |
| Rubin, RH | 1 |
| Werner, BG | 1 |
| Flores-Aguilar, M | 2 |
| Quiceno, JI | 2 |
| Dankner, WM | 1 |
| Capparelli, EV | 1 |
| Connor, JD | 1 |
| Sherwood, CH | 1 |
| Fullerton, S | 1 |
| Gambertoglio, JG | 1 |
| Weber, B | 1 |
| Chenot, JF | 1 |
| Scholz, M | 1 |
| Encke, A | 1 |
| Brerra, R | 1 |
| Barbi, M | 2 |
| Giezendanner, S | 1 |
| Wirth, HP | 1 |
| Zala, G | 1 |
| Weber, R | 1 |
| Flury, R | 1 |
| Meyenberger, C | 1 |
| Azad, RF | 1 |
| Brown-Driver, V | 1 |
| Buckheit, RW | 1 |
| Anderson, KP | 1 |
| Cohen, BA | 1 |
| Underwood, MR | 1 |
| Stanat, SC | 1 |
| Biron, KK | 3 |
| Silini, E | 2 |
| Desatnik, HR | 1 |
| Foster, RE | 2 |
| Lowder, CY | 2 |
| Enger, C | 2 |
| Bressler, N | 1 |
| Dodds, EM | 1 |
| Prayson, RA | 1 |
| Lazzarin, A | 1 |
| Ljungman, P | 2 |
| Loré, K | 1 |
| Aschan, J | 2 |
| Klaesson, S | 1 |
| Lewensohn-Fuchs, I | 1 |
| Lönnqvist, B | 3 |
| Ringdén, O | 4 |
| Winiarski, J | 2 |
| Ehrnst, A | 1 |
| Flaherty, JF | 1 |
| Hardy, D | 1 |
| Reusser, P | 1 |
| Einsele, H | 4 |
| Engelhard, D | 1 |
| Link, D | 1 |
| Locasciulli, A | 1 |
| Isaza, A | 1 |
| Lamparelli, T | 3 |
| Marmont, AM | 1 |
| Hostetler, KY | 4 |
| Kini, GD | 4 |
| Beadle, JR | 4 |
| Aldern, KA | 4 |
| Gardner, MF | 3 |
| Border, R | 1 |
| Kumar, R | 1 |
| Barshak, L | 1 |
| Sridhar, CN | 1 |
| Wheeler, CJ | 1 |
| Richman, DD | 3 |
| Nasir, MA | 1 |
| Jaffe, GJ | 1 |
| Craigen, JL | 1 |
| Grundy, JE | 1 |
| Gotti, E | 1 |
| Suter, F | 1 |
| Baruzzo, S | 1 |
| Perani, V | 1 |
| Moioli, F | 1 |
| Remuzzi, G | 1 |
| Rosen, HR | 1 |
| Benner, KG | 1 |
| Flora, KD | 1 |
| Rabkin, JM | 1 |
| Orloff, SL | 1 |
| Olyaei, A | 1 |
| Fletcher, CV | 1 |
| Erice, A | 3 |
| Henry, WK | 1 |
| Acosta, EP | 1 |
| Smith, SA | 1 |
| Holm, MA | 1 |
| Shepp, DH | 2 |
| Crumpacker, CS | 2 |
| Eaton, CA | 1 |
| Martin-Munley, SS | 1 |
| Gil-Roda, C | 1 |
| Pérez, JL | 2 |
| Sannerud, KJ | 1 |
| Hanson, MN | 1 |
| Macartney, M | 1 |
| Gane, EJ | 1 |
| Portmann, B | 1 |
| Williams, R | 1 |
| Flood, J | 1 |
| Miner, R | 3 |
| Jekic-McMullen, D | 1 |
| Shen, LP | 1 |
| Kolberg, J | 1 |
| Garvey, J | 1 |
| Follansbee, S | 1 |
| Poscher, M | 1 |
| Guentzel, S | 1 |
| Follansbee, SE | 1 |
| Poscher, ME | 1 |
| Lalezari, JP | 2 |
| Lipson, SM | 1 |
| Soni, M | 1 |
| Biondo, FX | 1 |
| Kaplan, MH | 1 |
| Sun, T | 1 |
| Manfredi, R | 1 |
| Lazzarotto, T | 1 |
| Spezzacatena, P | 1 |
| Dal Monte, P | 1 |
| Mastroianni, A | 1 |
| Coronado, OV | 1 |
| Chiodo, F | 1 |
| Hägglund, H | 1 |
| Sparrelid, E | 1 |
| Ericzon, BG | 1 |
| Hostetler, SE | 1 |
| Hebart, H | 3 |
| Kanz, L | 2 |
| Takahashi, K | 1 |
| Barbanti, M | 1 |
| Sacchi, N | 1 |
| Ficai, G | 1 |
| Ghinatti, C | 1 |
| Ferrara, GB | 1 |
| Delfino, L | 1 |
| Pozzi, S | 1 |
| Morabito, A | 1 |
| Zikos, P | 2 |
| Vitale, V | 1 |
| Corvo, R | 1 |
| Anders, HJ | 1 |
| Weiss, N | 1 |
| Bogner, JR | 1 |
| Goebel, FD | 1 |
| Tural, C | 1 |
| Romeu, J | 1 |
| Sirera, G | 1 |
| Andreu, D | 1 |
| Conejero, M | 1 |
| Ruiz, S | 1 |
| Jou, A | 1 |
| Bonjoch, A | 1 |
| Ruiz, L | 1 |
| Arnó, A | 1 |
| Clotet, B | 1 |
| Monno, L | 1 |
| Di Stefano, M | 1 |
| Zimatore, GB | 1 |
| Andreula, CF | 1 |
| Appice, A | 1 |
| Perulli, LM | 1 |
| Fiore, JR | 1 |
| Pastore, G | 1 |
| Angarano, G | 1 |
| Cihlar, T | 1 |
| Fuller, MD | 2 |
| Cherrington, JM | 2 |
| Ries, E | 1 |
| Mühlbauer, B | 1 |
| Ruhswurm, I | 1 |
| Krepler, K | 1 |
| Derbolav, A | 1 |
| Svolba, G | 1 |
| Rieger, A | 1 |
| Wedrich, A | 1 |
| Parenti, DM | 1 |
| LaVoy, AG | 1 |
| Ross, JG | 1 |
| Torsellini, M | 1 |
| Moretti, S | 1 |
| Mordini, N | 1 |
| Berisso, G | 1 |
| Bruno, B | 1 |
| Prix, L | 2 |
| Maierl, J | 1 |
| Lamy, PD | 1 |
| Nuessle, S | 1 |
| Wright, KN | 1 |
| Wald, A | 1 |
| Mattson, D | 1 |
| Schubert, MA | 1 |
| Stocchi, R | 1 |
| Ward, KN | 1 |
| Fanin, R | 1 |
| Baccarani, M | 1 |
| Apperley, JF | 1 |
| Handfield, J | 1 |
| Toma, E | 1 |
| Lalonde, R | 1 |
| Bergeron, MG | 1 |
| Iten, A | 1 |
| Chatelard, P | 1 |
| Vuadens, P | 1 |
| Miklossy, J | 1 |
| Meuli, R | 1 |
| Sahli, R | 1 |
| Meylan, PR | 1 |
| Cai, GY | 1 |
| Sharma, PL | 1 |
| Cheng, L | 1 |
| Avila, CP | 1 |
| Bergeron-Lynn, G | 1 |
| Keefe, KS | 2 |
| Wiley, CA | 2 |
| Freeman, WR | 2 |
| Waldman, WJ | 2 |
| Knight, DA | 2 |
| Miller, DM | 1 |
| Sedmak, DD | 1 |
| Williams, JW | 1 |
| Chong, AS | 1 |
| Manso, JV | 1 |
| Lambert, JL | 1 |
| Oña, M | 1 |
| de la Iglesia, JL | 1 |
| Iglesias, J | 1 |
| Hyun, JJ | 1 |
| Park, HS | 1 |
| Kim, KH | 1 |
| Maloisel, JL | 1 |
| Pring, BG | 1 |
| Tidén, AK | 1 |
| Dypbukt, J | 1 |
| Ljungdahl-Ståhle, E | 1 |
| Landry, ML | 1 |
| Stanat, S | 1 |
| Biron, K | 1 |
| Brambilla, D | 1 |
| Britt, W | 1 |
| Jokela, J | 1 |
| Gilliam, B | 1 |
| Manischewitz, J | 1 |
| Reichelderfer, P | 1 |
| Spector, S | 1 |
| Neyts, J | 2 |
| Sandvold, ML | 1 |
| Myhren, F | 1 |
| Anduze-Faris, BM | 1 |
| Lancar, R | 1 |
| Boukli, N | 1 |
| Gasnault, J | 1 |
| Caumes, E | 1 |
| Livartowsky, J | 1 |
| Matheron, S | 1 |
| Salmon, D | 1 |
| Costagliola, D | 1 |
| Sozzani, S | 1 |
| Lanzarini, P | 1 |
| Genini, E | 1 |
| Lilleri, D | 1 |
| Salmon-Céron, D | 1 |
| Aboulker, JP | 1 |
| Gérard, L | 1 |
| Houhou, N | 1 |
| Carrière, I | 1 |
| Ostinelli, J | 1 |
| Rubin, DI | 1 |
| Limaye, AP | 1 |
| Corey, L | 2 |
| Koelle, DM | 1 |
| Davis, CL | 1 |
| Boeckh, M | 2 |
| Sundqvist, VA | 1 |
| Linde, A | 3 |
| Eckle, T | 1 |
| Klingebiel, T | 1 |
| Handgretinger, R | 1 |
| Selle, B | 1 |
| Ketteler, M | 1 |
| Preuschof, L | 1 |
| Mertz, A | 1 |
| Stöffler-Meilicke, M | 1 |
| Schäfer, H | 2 |
| Distler, A | 1 |
| Offermann, G | 1 |
| Peggs, KS | 1 |
| Preiser, W | 1 |
| Kottaridis, PD | 1 |
| McKeag, N | 1 |
| Brink, NS | 1 |
| Tedder, RS | 1 |
| Goldstone, AH | 1 |
| Linch, DC | 1 |
| Mackinnon, S | 1 |
| Fassas, AB | 1 |
| Bolaños-Meade, J | 1 |
| Buddharaju, LN | 1 |
| Rapoport, A | 1 |
| Cottler-Fox, M | 1 |
| Chen, T | 1 |
| Lovchik, JC | 1 |
| Cross, A | 1 |
| Tricot, G | 1 |
| Crippa, F | 1 |
| Chuang, EL | 1 |
| Sale, G | 1 |
| Brugger, W | 1 |
| Grigoleit, U | 1 |
| Gscheidle, B | 1 |
| Loeffler, J | 1 |
| Sinzger, C | 1 |
| Blanchet, KD | 1 |
| Palestine, AG | 1 |
| Mascolini, M | 1 |
| Greijer, AE | 1 |
| Verschuuren, EA | 1 |
| Dekkers, CA | 1 |
| Adriaanse, HM | 1 |
| van der Bij, W | 1 |
| The, TH | 1 |
| Middeldorp, JM | 1 |
| Kiehl, MG | 1 |
| Basara, N | 1 |
| Castagnola, E | 1 |
| Miano, M | 1 |
| Morreale, G | 1 |
| Cristina, E | 1 |
| Chierici, M | 1 |
| Lanino, E | 1 |
| Ohta, H | 1 |
| Matsuda, Y | 1 |
| Tokimasa, S | 1 |
| Sawada, A | 1 |
| Kim, JY | 1 |
| Sashihara, J | 1 |
| Amo, K | 1 |
| Miyagawa, H | 1 |
| Tano, Y | 1 |
| Aono, T | 1 |
| Yamanishi, K | 1 |
| Okada, S | 1 |
| Hara, J | 1 |
| Harmenberg, J | 2 |
| Otegui, M | 1 |
| Rabella, N | 1 |
| Labeaga, R | 1 |
| Herrero, M | 1 |
| Margall, R | 1 |
| Muñoz, JM | 1 |
| Prats, G | 1 |
| Chakrabarti, S | 1 |
| Collingham, KE | 1 |
| Osman, H | 1 |
| Fegan, CD | 1 |
| Milligan, DW | 1 |
| Numazaki, K | 1 |
| LeClaire, JD | 1 |
| Hökeberg, I | 1 |
| Zweygberg-Wirgart, B | 1 |
| Grillner, L | 1 |
| Cañizares, MA | 1 |
| Losada, I | 1 |
| Pérez-Elías, MJ | 1 |
| González, J | 1 |
| Rubio, R | 1 |
| Casado, JL | 1 |
| Guerrero, A | 1 |
| Chou, SW | 1 |
| Assi, AC | 1 |
| Lightman, S | 1 |
| Mylonakis, E | 1 |
| Kallas, WM | 1 |
| Fishman, JA | 1 |
| Cerrina, J | 1 |
| Le Roy Ladurie, F | 1 |
| Peters, M | 1 |
| Timm, U | 1 |
| Schürmann, D | 1 |
| Pohle, HD | 1 |
| Ruf, B | 1 |
| Tatarowicz, WA | 1 |
| Thompson, KD | 1 |
| Peterson, TJ | 1 |
| Crapotta, J | 1 |
| Listhaus, AD | 1 |
| Blair, SD | 1 |
| Forbes, A | 1 |
| Parkins, RA | 1 |
| Jacobson, MA | 1 |
| Feinberg, J | 1 |
| O'Donnell, JJ | 1 |
| Whitmore, PV | 1 |
| Miner, RD | 1 |
| Parenti, D | 1 |
| Drobyski, WR | 2 |
| Knox, KK | 2 |
| Carrigan, DR | 2 |
| Ash, RC | 1 |
| Sullivan, V | 1 |
| Coen, DM | 1 |
| Smyth, RL | 1 |
| Scott, JP | 1 |
| Borysiewicz, LK | 1 |
| Sharples, LD | 1 |
| Stewart, S | 1 |
| Wreghitt, TG | 1 |
| Gray, JJ | 1 |
| Higenbottam, TW | 1 |
| Wallwork, J | 1 |
| Parea, M | 1 |
| Gaballo, A | 1 |
| Milanesi, G | 1 |
| Schols, D | 1 |
| Himpens, B | 1 |
| Chrisp, P | 1 |
| Clissold, SP | 1 |
| Bakker-Woudenberg, IA | 1 |
| Lokerse, AF | 1 |
| ten Kate, M | 1 |
| Youle, M | 1 |
| Chanas, A | 1 |
| Gazzard, B | 1 |
| Manischewitz, JF | 1 |
| Quinnan, GV | 1 |
| Lane, HC | 1 |
| Wittek, AE | 1 |
| Lagneaux, L | 1 |
| Delforge, A | 1 |
| Bron, D | 1 |
| Van der Auwera, P | 1 |
| Stryckmans, P | 1 |
| Eriksson, BF | 1 |
| Sundberg, B | 1 |
| Andersson, J | 1 |
| Akesson-Johansson, A | 2 |
| Brattström, C | 1 |
| Freitas, VR | 1 |
| Fraser-Smith, EB | 1 |
| Matthews, TR | 1 |
| Anders, DG | 2 |
| Kidd, JR | 1 |
| Gibson, W | 3 |
| Lee, JY | 1 |
| Irmiere, A | 2 |
| Bergman, J | 1 |
| Akerfeldt, S | 1 |
| Lundblad, L | 1 |
| Dolin, R | 1 |
| Rudén, U | 1 |
| Gadler, H | 1 |
| Eriksson, B | 1 |
| Tyms, AS | 1 |
| Davis, JM | 1 |
| Clarke, JR | 1 |
| Jeffries, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory[NCT02931539] | Phase 3 | 352 participants (Actual) | Interventional | 2016-12-22 | Completed | ||
| A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis[NCT00001061] | Phase 2 | 167 participants | Interventional | Completed | |||
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All-cause mortality was analyzed by the end of study regardless of the use of rescue treatment or alternative anti-CMV treatment. Number of participants who died during the entire study period were reported. (NCT02931539)
Timeframe: From enrollment up to end of study (approximately 44 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 13 |
| Maribavir 400 mg | 27 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: Up to Week 16
| Intervention | percentage of participants (Number) |
|---|---|
| Maribavir Rescue Arm | 27.3 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: From start of maribavir rescue treatment through 8 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Maribavir Rescue Arm | 50.0 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration less than (<) lower limit of quantification (LLOQ) that is, <137 International Units per milliliter (IU/mL) when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive postbaseline samples, separated by at least 5 days. Percentage of participants with confirmed CMV viremia clearance at end of study Week 8 regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy, and could not have received alternative anti-CMV treatment were reported. (NCT02931539)
Timeframe: Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 23.9 |
| Maribavir 400 mg | 55.7 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: Up to Week 16
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 10.3 |
| Maribavir 400 mg | 18.7 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants who completed 8 weeks of study-assigned treatment with recurrence of CMV viremia during the 12 weeks of follow-up period were reported. (NCT02931539)
Timeframe: End of Week 8 up to Week 20 (12 weeks follow-up period)
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 35.5 |
| Maribavir 400 mg | 40.9 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants who completed 8 weeks of study-assigned treatment with recurrence of CMV viremia during the 20 weeks of study were reported. (NCT02931539)
Timeframe: Baseline up to Week 20
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 45.2 |
| Maribavir 400 mg | 56.1 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with recurrence of CMV viremia during the first 8 Weeks of the treatment who completed 8 weeks of study-assigned treatment were reported. (NCT02931539)
Timeframe: Baseline up to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 9.7 |
| Maribavir 400 mg | 15.2 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. Percentage of participants with recurrence of CMV viremia during at any time on study regardless of whether study-assigned treatment was discontinued before 8 weeks of therapy were reported. (NCT02931539)
Timeframe: Baseline up to Week 20
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 33.8 |
| Maribavir 400 mg | 56.5 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. Percentage of participants with recurrence of CMV viremia during the 12 weeks follow-up period regardless of whether study-assigned treatment was discontinued before 8 weeks of therapy were reported. (NCT02931539)
Timeframe: End of Week 8 up to Week 20 (12 weeks follow-up period)
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 21.5 |
| Maribavir 400 mg | 38.6 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration greater than or equal to (>=) LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. Percentage of participants with recurrence of CMV viremia during the first 8 weeks of study regardless of whether study-assigned treatment was discontinued before 8 weeks of therapy were reported. (NCT02931539)
Timeframe: At Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 12.3 |
| Maribavir 400 mg | 17.9 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with recurrence of CMV viremia while off study-assigned treatment during follow-up period were reported. (NCT02931539)
Timeframe: Termination of study treatment (Week 8) up to the End of the Study (Week 20)
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 29.2 |
| Maribavir 400 mg | 40.8 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with recurrence of CMV viremia while on study-assigned treatment period were reported. (NCT02931539)
Timeframe: Baseline up to termination of study treatment (up to Week 8)
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 4.6 |
| Maribavir 400 mg | 15.8 |
The time to all-cause mortality by the end of the study participation in days was calculated. Participants who were alive at the last study follow-up (regardless of use of rescue or alternative anti-CMV treatment), withdrew from study or were lost to follow-up were censored at the date of last contact. (NCT02931539)
Timeframe: From enrollment to last serious adverse event (SAE) follow-up (approximately Week 28)
| Intervention | days (Median) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 73.0 |
| Maribavir 400 mg | 55.0 |
Resistance-associated amino acid substitutions (RASs) to maribavir are known to generally map to the pUL97 and pUL27 genes. Genotyping was performed to identify RASs mapping to the pUL97 and pUL27 genes. Number of participants who had maribavir CMV resistance at baseline were reported. (NCT02931539)
Timeframe: At Baseline
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| RASs associated with pUL97 only | RASs associated with pUL27 only | RASs associated with pUL97 and pUL27 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 3 | 0 | 0 |
| Maribavir 400 mg | 0 | 1 | 0 |
| Maribavir Rescue Arm | 1 | 0 | 0 |
Resistance-associated amino acid substitutions (RASs) to maribavir are known to generally map to the pUL97 and pUL27 genes. Genotyping was performed to identify RASs mapping to the pUL97 and pUL27 genes. Number of participants who had post-baseline resistance to maribavir were reported. (NCT02931539)
Timeframe: After first dose of study drug up to Week 20
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| RASs associated with pUL97 only | RASs associated with pUL27 only | RASs associated with pUL97 and pUL27 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 0 | 0 | 0 |
| Maribavir 400 mg | 45 | 0 | 0 |
| Maribavir Rescue Arm | 4 | 0 | 0 |
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. Serious AE was any untoward medical occurrence (whether considered to be related to study-assigned treatment or not) that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital abnormality/birth defect, or was an important medical event. TEAEs was defined as any adverse events (classified by preferred term) that had a start date on or after the first dose of study treatment or that had a start date before the date of first dose of study treatment, but increased in severity after the first dose of study treatment. (NCT02931539)
Timeframe: Baseline up to 7 days or 21 days (if cidofovir used) after the last dose of study treatment (up to Week 8)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAEs | Serious TEAEs | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 106 | 43 |
| Maribavir 400 mg | 228 | 90 |
| Maribavir Rescue Arm | 22 | 11 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: At Week 8 through Weeks 12, 16 and 20
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| At Week 8 | At Week 12 | At Week 16 | At Week 20 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 18.8 | 5.1 | 5.1 | 4.3 |
| Maribavir 400 mg | 54.9 | 22.6 | 18.7 | 18.3 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: At Week 8 through Weeks 12, 16 and 20
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| At Week 8 | At Week 12 | At Week 16 | At Week 20 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 18.8 | 5.1 | 5.1 | 4.3 |
| Maribavir 400 mg | 54.9 | 22.6 | 18.7 | 18.3 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: At Week 8 through Weeks 12 and 20
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| At Week 8 | At Week 12 | At Week 20 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 23.9 | 10.3 | 9.4 |
| Maribavir 400 mg | 55.7 | 22.6 | 18.3 |
Cmin of maribavir was reported. (NCT02931539)
Timeframe: Predose at Week 1, 4 and 8
| Intervention | micrograms per milliliter (mcg/mL) (Mean) | ||
|---|---|---|---|
| Cmin at Week 1 | Cmin at Week 4 | Cmin at Week 8 | |
| Maribavir 400 mg | 8.77 | 7.59 | 7.19 |
| Maribavir Rescue Arm | 8.57 | 5.75 | 5.65 |
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
39 reviews available for foscarnet and Cytomegalovirus
| Article | Year |
|---|---|
Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Trans | 2023 |
Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.
Topics: Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Cytomegalovirus Vaccines; Dr | 2020 |
Resistant Cytomegalovirus Infection After Renal Transplantation: Literature Review.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antiviral Agents; Basiliximab; Cytomegalovirus; | 2018 |
New Developments in the Management of Cytomegalovirus Infection After Transplantation.
Topics: Acetates; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, | 2018 |
[Current treatment modalities of immunocompromised patients with cytomegalovirus infection. II. Therapeutic options and management strategies].
Topics: Acetates; Acyclovir; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganci | 2019 |
Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Drug Therapy, | 2013 |
Antiviral drug resistance in herpesviruses other than cytomegalovirus.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; Drug Resistance, Viral; Foscarnet | 2014 |
Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; Cyclosporine; Cytomegalovirus; Cytomegalovir | 2015 |
[Gastrointestinal cytomegalovirus infections in organ transplant patients].
Topics: Acyclovir; Antiviral Agents; Biopsy; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosin | 2008 |
CMV-related thrombocytopenia treated with foscarnet: a case series and review of the literature.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Therapy, Combination; Fem | 2010 |
Antiviral drug resistance of human cytomegalovirus.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2010 |
The search for new therapies for human cytomegalovirus infections.
Topics: Antiviral Agents; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; F | 2011 |
Prevention and management of CMV-related problems after hematopoietic stem cell transplantation.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Fosca | 2002 |
Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Cidofovir; Cytomegaloviru | 2004 |
Campylobacter fetus bacteremia in an immunocompromised patient: case report and review of the literature.
Topics: Adult; Bacteremia; Campylobacter fetus; Campylobacter Infections; Ciprofloxacin; Cytomegalovirus; Fe | 2004 |
[Human cytomegalovirus infection].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; gamma-Globulins; Ganciclov | 2005 |
Is combination antiviral therapy for CMV superior to monotherapy?
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Synergism; Drug Therapy, Combina | 2006 |
[Development of drug-resistant human cytomegalovirus].
Topics: Antiviral Agents; Cytomegalovirus; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Foscarnet; G | 2006 |
[Human cytomegalovirus infection].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Globins; Huma | 2007 |
[Mechanism of drug-resistance in human cytomegalovirus].
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2007 |
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus; Drug Administration Schedule; Drug Interacti | 1994 |
[Cytomegalovirus infection after transplantation. Virological diagnosis, antiviral treatment].
Topics: Antibodies, Viral; Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Enzyme- | 1993 |
New developments in cytomegalovirus prevention and management.
Topics: Antibodies, Viral; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Immu | 1993 |
[Active antiviral agents against human cytomegalovirus and their use in pediatrics].
Topics: Antiviral Agents; Child; Child, Preschool; Cytomegalovirus; Foscarnet; Ganciclovir; Humans; Infant | 1996 |
Therapeutic options for resistant cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus | 1997 |
Resistance to antivirals in human cytomegalovirus: mechanisms and clinical significance.
Topics: Antiviral Agents; Cidofovir; Codon; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 1997 |
Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Gu | 1998 |
[Recent advances in antiviral drugs--antiviral agents to HCMV, HHV-6, and HHV-7].
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 1998 |
Ganciclovir and foscarnet efficacy in AIDS-related CMV polyradiculopathy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Inf | 1998 |
Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised.
Topics: Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug Res | 1998 |
Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Topics: Acyclovir; Adolescent; Adult; Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Child; | 1999 |
Clinically resistant cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; | 1995 |
Cytomegalovirus infection following stem cell transplantation.
Topics: Acyclovir; Antibodies, Viral; Antiviral Agents; Blood Donors; Cidofovir; Cytomegalovirus; Cytomegalo | 1999 |
Progress in understanding cytomegalovirus drug resistance.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
[Cytomegalovirus infection].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Disease Transmission, Infectious; Fem | 2001 |
Cytomegalovirus drug resistance and clinical implications.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
[Cytomegalovirus infection in patients after lung transplantation].
Topics: Acyclovir; Antiviral Agents; Blood Transfusion; Cytomegalovirus; Cytomegalovirus Infections; Foscarn | 1992 |
Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. A case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1992 |
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Anemia; Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
18 trials available for foscarnet and Cytomegalovirus
| Article | Year |
|---|---|
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dichlororibofuranosylbenzimidazole; D | 2022 |
Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cohort Studies; Cytomegalovirus; Cyt | 2003 |
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bone Marrow Transplantation; Child; Child, Preschool; Cyt | 2004 |
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus re
Topics: Adult; AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antiviral Agents; Cytomegalovi | 2004 |
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus; Drug Administration Schedule; Drug Interacti | 1994 |
Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison.
Topics: Adult; AIDS-Related Opportunistic Infections; Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infe | 1995 |
Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
Topics: Adult; Anemia, Aplastic; Antigens, Viral; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovi | 1994 |
Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Aqueous Humor; Cytomegalovirus; Cytomegalovirus Retini | 1994 |
Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; DNA, Vir | 1996 |
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1996 |
Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1997 |
Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Infections; Femal | 1998 |
Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovir | 2000 |
Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group.
Topics: AIDS-Related Opportunistic Infections; Antigens, Viral; Antiviral Agents; Biomarkers; Cytomegaloviru | 1999 |
Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
Treatment of acquired immune deficiency syndrome (AIDS)-related pneumonitis with foscarnet: a double-blind placebo controlled study.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; D | 1990 |
Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Female; | 1986 |
Antiviral chemotherapy and chemoprophylaxis.
Topics: Acyclovir; Adult; Aged; Amantadine; Antiviral Agents; Chickenpox; Clinical Trials as Topic; Cytomega | 1985 |
233 other studies available for foscarnet and Cytomegalovirus
| Article | Year |
|---|---|
Benzimidazole ribonucleosides: design, synthesis, and antiviral activity of certain 2-(alkylthio)- and 2-(benzylthio)-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazoles.
Topics: Antiviral Agents; Cell Line; Cell Survival; Cytomegalovirus; Dichlororibofuranosylbenzimidazole; Dru | 1994 |
Design, synthesis, and antiviral evaluation of 2-substituted 4,5-dichloro- and 4,6-dichloro-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections.
Topics: Antiviral Agents; Benzimidazoles; Cell Division; Cell Line; Cytomegalovirus; Cytomegalovirus Infecti | 1997 |
Design, synthesis, and antiviral evaluation of 2-chloro-5,6-dihalo-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections.
Topics: Antiviral Agents; Benzimidazoles; Cell Division; Cell Line; Cytomegalovirus; Cytomegalovirus Infecti | 1997 |
Design, synthesis, and antiviral activity of alpha-nucleosides: D- and L-isomers of lyxofuranosyl- and (5-deoxylyxofuranosyl)benzimidazoles.
Topics: Antiviral Agents; Benzimidazoles; Cell Division; Cell Survival; Cytomegalovirus; Drug Design; Drug E | 1998 |
Synthesis and antiviral evaluation of trisubstituted indole N-nucleosides as analogues of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole (TCRB).
Topics: Antiviral Agents; Benzimidazoles; Cell Division; Cell Line; Cytomegalovirus; Enzyme-Linked Immunosor | 2000 |
Syntheses and structure--activity relationships of novel apio and thioapio dideoxydidehydronucleosides as anti-HCMV agents.
Topics: Antiviral Agents; Cell Line; Cytomegalovirus; Dideoxynucleosides; Herpesvirus 1, Human; Herpesvirus | 2001 |
Discovery of a new family of inhibitors of human cytomegalovirus (HCMV) based upon lipophilic alkyl furano pyrimidine dideoxy nucleosides: action via a novel non-nucleosidic mechanism.
Topics: Antiviral Agents; Cell Line; Cytomegalovirus; Furans; Humans; Pyrimidine Nucleosides; Structure-Acti | 2004 |
4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
Topics: Animals; Antiviral Agents; Cell Line; Cell Survival; Chlorocebus aethiops; Cytomegalovirus; DNA-Dire | 2005 |
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA Replication; | 2007 |
2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases.
Topics: Antiviral Agents; Binding, Competitive; Cytomegalovirus; DNA-Directed DNA Polymerase; Enzyme Inhibit | 2007 |
7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymerase.
Topics: Cytomegalovirus; Enzyme Inhibitors; Nucleic Acid Synthesis Inhibitors; Pyridines; Structure-Activity | 2007 |
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; Drug Res | 2007 |
Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Cytomegalovirus; Drug Design; Enzyme Inhibitors; Esters | 2008 |
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
Topics: Antiviral Agents; Cell Line; Cytomegalovirus; Humans; Magnetic Resonance Spectroscopy; Microbial Sen | 2008 |
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
Topics: Antiviral Agents; Cross-Linking Reagents; Cytomegalovirus; Drug Interactions; Foscarnet; Glyceryl Et | 2009 |
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Cytomegalovirus; Herpesvirus 3, Human; H | 2009 |
Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpesvirus antivirals with improved aqueous solubility.
Topics: Antiviral Agents; Cytomegalovirus; DNA-Directed DNA Polymerase; Herpesviridae; Herpesvirus 1, Human; | 2010 |
Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles for Effective Antiviral Therapy.
Topics: Antiviral Agents; Cytomegalovirus; Foscarnet; Herpesvirus 1, Human; Humans; Nanoparticles | 2022 |
Intra-host diversity of drug-resistant cytomegalovirus: A case report of cytomegalovirus infection after allogeneic hematopoietic cell transplantation.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Fo | 2022 |
Artificial stem cells mediated inflammation-tropic delivery of antiviral drugs for pneumonia treatment.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Fatty Acids, Monounsaturated; Foscarn | 2022 |
[Resistance to antiviral drugs in human viruses from the subfamily
Topics: Antiviral Agents; Betaherpesvirinae; Cytomegalovirus; Cytosine; DNA-Directed DNA Polymerase; Drug Re | 2022 |
[Resistance to antiviral drugs in human viruses from the subfamily
Topics: Antiviral Agents; Betaherpesvirinae; Cytomegalovirus; Cytosine; DNA-Directed DNA Polymerase; Drug Re | 2022 |
[Resistance to antiviral drugs in human viruses from the subfamily
Topics: Antiviral Agents; Betaherpesvirinae; Cytomegalovirus; Cytosine; DNA-Directed DNA Polymerase; Drug Re | 2022 |
[Resistance to antiviral drugs in human viruses from the subfamily
Topics: Antiviral Agents; Betaherpesvirinae; Cytomegalovirus; Cytosine; DNA-Directed DNA Polymerase; Drug Re | 2022 |
Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients.
Topics: Antiviral Agents; Benzimidazoles; Cidofovir; Cytomegalovirus; DNA-Directed DNA Polymerase; Drug Resi | 2023 |
Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
Topics: Aged; Antiviral Agents; Cytomegalovirus; Drug Resistance, Viral; Foscarnet; Hepatorenal Syndrome; Hu | 2019 |
Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Dosage Calculations; Fema | 2019 |
Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; DNA, Vir | 2020 |
Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Topics: beta-Thalassemia; Child; Cytomegalovirus; Cytomegalovirus Infections; Female; Foscarnet; Hematopoiet | 2021 |
Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy.
Topics: Antiviral Agents; Cytomegalovirus; Foscarnet; Ganciclovir; Humans; Neoplasm Recurrence, Local; Retro | 2021 |
Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet.
Topics: Amino Acid Substitution; Antiviral Agents; Cytomegalovirus; DNA-Directed DNA Polymerase; Drug Resist | 2021 |
Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Hum | 2021 |
Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2017 |
Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report.
Topics: Aged; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Dose-Respo | 2017 |
Viral reactivation imitates relapse of pemphigus vulgaris in an immunosuppressed patient.
Topics: Autoantibodies; Combined Modality Therapy; Cytomegalovirus; Debridement; Desmoglein 1; Desmoglein 3; | 2017 |
Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; | 2018 |
Antiviral combination therapy for cytomegalovirus infection in high-risk infants.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Fo | 2018 |
Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Female; Foscarnet; Humans; Male; Middle Aged; Unrelated Do | 2018 |
Optic Nerve Swelling in a Patient With Cancer.
Topics: Antiviral Agents; Aqueous Humor; Cytomegalovirus; Cytomegalovirus Retinitis; Diagnosis, Differential | 2018 |
In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
Topics: Antiviral Agents; Benzimidazoles; Cell Line; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovi | 2018 |
Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report.
Topics: Adolescent; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Microbia | 2018 |
Cytomegalovirus in Pediatric Hematopoietic Stem Cell Transplantation: A Case-Based Panel Discussion of Current Challenges.
Topics: Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Fatal | 2018 |
Cytomegalovirus retinitis in the absence of AIDS.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; DNA, V | 2013 |
Acute retinal necrosis secondary to cytomegalovirus following successful treatment of cytomegalovirus anterior uveitis in an immunocompetent adult.
Topics: Antiviral Agents; Aqueous Humor; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug Thera | 2013 |
Chronic retinal necrosis: cytomegalovirus necrotizing retinitis associated with panretinal vasculopathy in non-HIV patients.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Aqueous Humor; CD4 Lymphocyte Count; Chronic Disease; Cyt | 2013 |
Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Cells, Cultured; Chromosomes, Artificial, Bact | 2013 |
Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides.
Topics: Adolescent; Adult; Antigens, Viral; Antiviral Agents; Blood Donors; Combined Modality Therapy; Cytom | 2013 |
Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
Topics: Antiviral Agents; Chromosomes, Artificial, Bacterial; Cidofovir; Cytomegalovirus; Cytomegalovirus In | 2013 |
In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.
Topics: Antiviral Agents; Artemisinins; Butadienes; Cell Line; Cytomegalovirus; Digitoxin; Digoxin; Drug Com | 2014 |
Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives.
Topics: Antiviral Agents; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytosine; Drug Resistance, Multiple, Vi | 2014 |
UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2014 |
Preparation, characterization and in vitro antiviral activity evaluation of foscarnet-chitosan nanoparticles.
Topics: Antiviral Agents; Chitosan; Cytomegalovirus; Drug Stability; Endocytosis; Fibroblasts; Fluorescence; | 2014 |
Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2014 |
Cytomegalovirus retinitis in HIV-negative patients: a practical management approach.
Topics: Adult; Aged; Antigens, Viral; Antiviral Agents; Child, Preschool; Cytomegalovirus; Cytomegalovirus R | 2015 |
Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.
Topics: Acyclovir; Analysis of Variance; Animals; Antiviral Agents; Chlorocebus aethiops; Cytomegalovirus; D | 2015 |
Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis.
Topics: Antiviral Agents; Chromosomes, Artificial, Bacterial; Cytomegalovirus; Cytosine; DNA-Directed DNA Po | 2016 |
Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antiviral Agents; Cohort Studies; Commu | 2016 |
Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2016 |
Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Topics: Adolescent; Adult; Antiviral Agents; Child; Chromosomes, Artificial, Bacterial; Cidofovir; Cytomegal | 2016 |
Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients.
Topics: Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Female; | 2016 |
Ganciclovir and Foscarnet Therapy of Cytomegalovirus-Associated Meningoencephalitis in a Hemodialysis Patient With Liver Transplantation: Case Report.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Fo | 2016 |
Immune-based guidance of foscarnet treatment duration in a transplant recipient with ganciclovir-resistant cytomegalovirus infection.
Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalovirus; Cytomegalovirus Infections; Dr | 2016 |
Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
Topics: Aged; Antiviral Agents; Chemotherapy, Adjuvant; Cytomegalovirus; Cytomegalovirus Infections; Drug Mo | 2016 |
Cytomegalovirus sinusitis complicated by orbital apex syndrome in an immunocompromised host.
Topics: Aged; Antiviral Agents; Biopsy; Blindness; Cytomegalovirus; Cytomegalovirus Infections; Diplopia; Ex | 2016 |
Dual Intravitreal Injections With Foscarnet and Ganciclovir for Ganciclovir-Resistant Recurrent Cytomegalovirus Retinitis in a Congenitally Infected Infant.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resistance, Viral; Drug Therapy, | 2016 |
Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.
Topics: Amino Acid Substitution; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed | 2017 |
Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Topics: Alemtuzumab; Anemia, Refractory, with Excess of Blasts; Antibodies, Monoclonal; Antibodies, Monoclon | 2008 |
Low-dose foscarnet preemptive therapy for cytomegalovirus viremia after haploidentical bone marrow transplantation.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Female; | 2009 |
Cytomegalovirus retinitis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antibo | 2009 |
[Disease by CMV resistant to Ganciclovir. Should plasma valganciclovir levels be monitored in high risk patients?].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Monitoring; Drug Resistance, Mul | 2009 |
Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT.
Topics: Acyclovir; Adolescent; Adult; Antibodies, Viral; Antigens, Viral; Antiviral Agents; Child; Child, Pr | 2009 |
Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.
Topics: Acyclovir; Antiviral Agents; Binding Sites; Catalysis; Cytomegalovirus; Deoxycytosine Nucleotides; D | 2009 |
Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agent | 2010 |
Long-term follow-up of acute retinal necrosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Infections; Drug | 2010 |
Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity.
Topics: Animals; Antiviral Agents; Cells, Cultured; Cytomegalovirus; DNA-Directed DNA Polymerase; Drug Resis | 2010 |
Analysis of human cytomegalovirus glycoprotein N genotypes in Chinese hematopoietic stem cell transplant recipients.
Topics: Antiviral Agents; China; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Female; Foscarnet; | 2011 |
Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.
Topics: Antiviral Agents; Chromosomes, Artificial, Bacterial; Cytomegalovirus; Cytomegalovirus Infections; D | 2011 |
Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase.
Topics: Acyclovir; Amino Acid Substitution; Crystallography, X-Ray; Cytomegalovirus; DNA-Directed DNA Polyme | 2011 |
Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cytomegalovir | 2011 |
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; DNA-Directed DNA Polymerase; Foscarnet; Ganciclo | 2011 |
Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
Topics: Alkaline Phosphatase; Antiviral Agents; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovirus I | 2012 |
Polymerase chain reaction-based ganciclovir resistance testing of ocular fluids for cytomegalovirus retinitis.
Topics: Adult; Aged; Antiviral Agents; Aqueous Humor; Cytomegalovirus; Cytomegalovirus Retinitis; DNA-Direct | 2012 |
Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis; Cytosine; DNA, Viral | 2012 |
Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 2012 |
Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2012 |
The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection.
Topics: Adult; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet; Ganci | 2013 |
A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma in a patient with systemic non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Cytomegalovirus; Cy | 2013 |
Z-isomers of 2-hydroxymethylcyclopropylidenemethyl adenine (synadenol) and guanine (synguanol) are active against ganciclovir- and foscarnet-resistant human cytomegalovirus UL97 mutants.
Topics: Adenine; Antiviral Agents; Cyclopropanes; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistan | 2002 |
Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection.
Topics: Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Drug Therapy, Combination; Fema | 2002 |
Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; D | 2002 |
Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase.
Topics: Amino Acid Substitution; Cells, Cultured; Codon; Cytomegalovirus; DNA-Directed DNA Polymerase; Drug | 2003 |
Synergy of bovine lactoferrin with the anti-cytomegalovirus drug cidofovir in vitro.
Topics: Acyclovir; Animals; Antiviral Agents; Cattle; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytosine; | 2003 |
Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy.
Topics: Aged; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA, Viral | 2004 |
Susceptibility of porcine cytomegalovirus to antiviral drugs.
Topics: Animals; Antiviral Agents; Cell Survival; Cidofovir; Cytomegalovirus; Cytosine; DNA, Viral; Fluoresc | 2004 |
Encephalitis owing to human herpesvirus-6 after cardiac transplant.
Topics: Adult; Antiviral Agents; Cytomegalovirus; DNA, Viral; Encephalitis; Foscarnet; Heart Transplantation | 2004 |
Foscarnet therapy for congenital cytomegalovirus liver fibrosis following prenatal ascites.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Diagnosis, Differential; DNA, | 2004 |
How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients.
Topics: Adolescent; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; E | 2005 |
Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet.
Topics: Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Fo | 2005 |
Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.
Topics: Amino Acid Sequence; Amino Acid Substitution; Animals; Antiviral Agents; Base Sequence; Binding Site | 2006 |
Diagnosis and treatment of cytomegalovirus iridocyclitis without retinal necrosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Chronic Disease; Cytomegalovirus; Cyto | 2006 |
Antiviral properties of new arylsulfone derivatives with activity against human betaherpesviruses.
Topics: Antiviral Agents; Cell Line; Cytomegalovirus; DNA, Viral; Dose-Response Relationship, Drug; Drug Syn | 2006 |
A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; Drug Res | 2006 |
Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
Topics: Antiviral Agents; Benzimidazoles; Cidofovir; Cytomegalovirus; Cytosine; DNA-Directed DNA Polymerase; | 2006 |
Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet.
Topics: Antiviral Agents; Catalytic Domain; Colorimetry; Cytomegalovirus; Digoxigenin; DNA-Directed DNA Poly | 2007 |
Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation.
Topics: Adolescent; Adult; Aged; Antigens, Viral; Antiviral Agents; Cord Blood Stem Cell Transplantation; Cy | 2007 |
Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients.
Topics: Adolescent; Adult; Aged; Cord Blood Stem Cell Transplantation; Cytomegalovirus; Cytomegalovirus Infe | 2007 |
Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Disease Progression; DNA | 2007 |
Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child.
Topics: Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Infections; Drug Monitoring; Drug Resistan | 2007 |
Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
Topics: Antibodies, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug R | 2007 |
Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet.
Topics: Amino Acid Sequence; Antiviral Agents; Catalytic Domain; Cell Line; Cytomegalovirus; DNA-Directed DN | 2007 |
Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Cells, Cultured; Cid | 2008 |
A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Drug T | 2007 |
Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation.
Topics: Antiviral Agents; Artemisinins; Artesunate; Child; Cytomegalovirus; Cytomegalovirus Infections; Drug | 2008 |
Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2008 |
Conditions for cytomegalovirus stimulation of lymphocytes.
Topics: Antibodies, Viral; Antigens, Viral; Antiviral Agents; Cells, Cultured; Cytomegalovirus; DNA Replicat | 1981 |
Effects of acyclovir combined with other antiviral agents on human cytomegalovirus.
Topics: Acyclovir; Antiviral Agents; Cell Line; Cytomegalovirus; Drug Evaluation, Preclinical; Drug Synergis | 1982 |
Inhibition of cytomegalovirus late antigens by phosphonoformate.
Topics: Antigens, Viral; Cell Line; Cytomegalovirus; Cytopathogenic Effect, Viral; DNA-Directed DNA Polymera | 1980 |
Reversible inhibition of cytomegalovirus replication by phosphonoformate.
Topics: Animals; Antigens, Viral; Antiviral Agents; Cells, Cultured; Cricetinae; Cytomegalovirus; Foscarnet; | 1980 |
Inhibition of human cytomegalovirus by trifluorothymidine.
Topics: Acyclovir; Cytomegalovirus; Foscarnet; Humans; Interferon Type I; Lung; Phosphonoacetic Acid; Thymid | 1983 |
A sensitive and specific polymerase chain reaction-based assay for the diagnosis of cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Base Sequence; Cytomegalovirus; Cytomegalovirus Retinitis; DN | 1995 |
Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus; Cytomegalovirus Retinitis; Disease Pr | 1995 |
[Clinical value of a polymerase chain reaction on cytomegalovirus DNA in cerebrospinal fluid in HIV patients with neurological symptoms].
Topics: Adult; AIDS Dementia Complex; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Encephalitis, | 1995 |
Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples.
Topics: Antigens, Viral; Blood; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Microbial; Fos | 1995 |
[Quantitative cytomegaloviral leukocytic antigenemia. Clinical aspects].
Topics: Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Kidney | 1995 |
Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication.
Topics: Antibodies, Monoclonal; Antibodies, Viral; Cytomegalovirus; Drug Synergism; Foscarnet; Ganciclovir; | 1994 |
Cytomegalovirus multifocal neuropathy in AIDS: analysis of 15 consecutive cases.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; | 1994 |
Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Drug Ad | 1994 |
Polyradiculopathy due to cytomegalovirus infection: report of a case in which an AIDS patient responded to foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus; C | 1994 |
In vitro anti-human cytomegalovirus activity of liposome-encapsulated foscarnet.
Topics: Cells, Cultured; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Carriers; Fibroblasts; Foscarnet; | 1994 |
Rapid detection of cytomegalovirus strains resistant to ganciclovir through mutations within the gene UL97.
Topics: Base Sequence; Bronchoalveolar Lavage Fluid; Cerebrospinal Fluid; Cytomegalovirus; Cytomegalovirus I | 1993 |
Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus.
Topics: Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resistance, Microbial; Foscarnet; Ganciclovir; HIV | 1993 |
Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus; Cytomegalovirus Infections; Drug Resi | 1993 |
In vitro inhibition of human cytomegalovirus replication in human foreskin fibroblasts and endothelial cells by ascorbic acid 2-phosphate.
Topics: Antigens, Viral; Antiviral Agents; Ascorbic Acid; Cells, Cultured; Cytomegalovirus; Endothelium; Fib | 1995 |
Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cell Line; Cytomegalovirus; Cytomega | 1995 |
[Clinical manifestations and course of cytomegalovirus colitis in AIDS patients].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cohort Studies; Colitis; Colonoscopy | 1995 |
Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs.
Topics: Antiviral Agents; Base Sequence; Cell Line; Cytomegalovirus; Drug Interactions; Foscarnet; Ganciclov | 1995 |
Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Base Sequence; Cerebrospi | 1996 |
Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered f
Topics: AIDS-Related Opportunistic Infections; Amino Acid Sequence; Base Sequence; Cytomegalovirus; Cytomega | 1996 |
Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Ret | 1996 |
Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Baltimore; Cytomegalovirus; Cytomega | 1996 |
Serous retinal detachments in a patient with clinically resistant cytomegalovirus retinitis.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomega | 1996 |
Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1995 |
Current and experimental therapeutic options for cytomegalovirus disease.
Topics: Administration, Oral; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cyto | 1996 |
Current management of cytomegalovirus infection: treatment and prophylaxis.
Topics: Administration, Oral; Anti-Bacterial Agents; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Reti | 1996 |
Cytomegalovirus resistance to antiviral therapies.
Topics: Administration, Oral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance | 1996 |
European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Topics: Acyclovir; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Data Collection; Drug Res | 1996 |
Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antibodies, Viral; Cell Transplantation; Cyclosporine; Cytomegalovirus; Cytomegal | 1996 |
Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro.
Topics: Anti-HIV Agents; Antiviral Agents; Cell Line; Cytomegalovirus; DNA, Viral; Foscarnet; Herpesvirus 1, | 1996 |
Cytomegalovirus retinitis associated with Hodgkin's disease.
Topics: Adult; Antiviral Agents; Biopsy; Cytomegalovirus; Cytomegalovirus Retinitis; DNA, Viral; Fluorescein | 1996 |
Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro.
Topics: Acyclovir; Adenine; Antiviral Agents; Cells, Cultured; Cidofovir; Cytarabine; Cytomegalovirus; Cytom | 1996 |
Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment.
Topics: Antiviral Agents; Bone Marrow Transplantation; CD58 Antigens; Cytomegalovirus; Cytomegalovirus Infec | 1996 |
Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Topics: Adolescent; Adult; Antigens, Viral; Antiviral Agents; Chemoprevention; Child; Cytomegalovirus; Cytom | 1996 |
Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation.
Topics: Adolescent; Cytomegalovirus; Cytomegalovirus Infections; DNA Mutational Analysis; Drug Resistance, M | 1997 |
Quantitative systemic and local evaluation of the antiviral effect of ganciclovir and foscarnet induction treatment on human cytomegalovirus gastrointestinal disease of patients with AIDS. Italian Foscarnet GID Study Group.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1997 |
Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Base Sequence; Cytomegalovirus; Cytomegalov | 1997 |
Comparison of a new quantitative cytomegalovirus DNA assay with other detection methods.
Topics: Antibodies, Viral; Antiviral Agents; Biopsy; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infec | 1997 |
Diagnosis of cytomegalovirus (CMV) polyradiculopathy and documentation of in vivo anti-CMV activity in cerebrospinal fluid by using branched DNA signal amplification and antigen assays.
Topics: Antigens, Viral; Antiviral Agents; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; Cyt | 1997 |
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cidofovir; Cytomega | 1997 |
Antiviral susceptibility testing-flow cytometric analysis (AST-FCA) for the detection of cytomegalovirus drug resistance.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Dose-Response Relationship, Drug; Flow Cytometry | 1997 |
Quantitative cytomegalovirus (CMV) antigenaemia during antiviral treatment of AIDS-related CMV disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Antigens, Viral; Antiviral Agents; Biomarkers; Cytomeg | 1997 |
Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV.
Topics: Antiviral Agents; Cell Line; Cell Survival; Cytomegalovirus; Foscarnet; Herpesvirus 1, Human; HIV-1; | 1997 |
Successful allogeneic bone marrow transplantation in a 2.5-year-old boy with ongoing cytomegalovirus viremia and severe aplastic anemia after orthotopic liver transplantation for non-A, non-B, non-C hepatitis.
Topics: Anemia, Aplastic; Antiviral Agents; Biopsy; Bone Marrow; Bone Marrow Transplantation; Child, Prescho | 1997 |
Synthesis and antiviral activity of 1-O-octadecyl-2-O-alkyl-sn-glycero-3-foscarnet conjugates in human cytomegalovirus-infected cells.
Topics: Antiviral Agents; Cell Line; Cytomegalovirus; Foscarnet; Humans | 1997 |
Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Topics: Acyclovir; Adolescent; Adult; Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Cause | 1997 |
Interpreting human cytomegalovirus antiviral drug susceptibility testing: the role of mixed virus populations.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; Drug Resistance, Microbial; Foscarnet; Ganci | 1998 |
Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cytomegalovirus | 1998 |
Measurement of viral sequences in cerebrospinal fluid of AIDS patients with cerebral white-matter lesions using polymerase chain reaction.
Topics: Adolescent; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Br | 1998 |
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; DNA Replication; DNA-Directed DNA Polymerase | 1998 |
Evaluation of cytomegalovirus retinitis management. Outcome of four years of cytomegalovirus therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Body Fluids; CD4 Lymphocyte Count; Cytomega | 1998 |
Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Alanine; Antiviral Agents; Cytomegalovirus; Cytomegalo | 1998 |
Diagnostic significance and clinical impact of quantitative assays for diagnosis of human cytomegalovirus infection/disease in immunocompromised patients.
Topics: AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antigens, Viral; Antiviral Agents; Ce | 1998 |
Cytomegalovirus retinitis and viral resistance: 3. Culture results. CMV Retinitis and Viral Resistance Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Baltimore; Blood; Cidofovir; Cytomeg | 1998 |
A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains.
Topics: Antiviral Agents; Coculture Techniques; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance | 1998 |
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis; Cytosine; Drug Resistance, | 1998 |
Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells.
Topics: Administration, Oral; Animals; Antiviral Agents; Biological Availability; Cells, Cultured; Cytomegal | 1998 |
Photo quiz. Foscarnet-induced genital ulcers.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Female; Foscarnet; Genital Diseases, | 1999 |
Expression of the late cytomegalovirus (CMV) pp150 transcript in leukocytes of AIDS patients is associated with a high viral DNA load in leukocytes and presence of CMV DNA in plasma.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1999 |
Impact of cerebrospinal fluid PCR on the management of HIV-infected patients with varicella-zoster virus infection of the central nervous system.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Central Nervous System In | 1999 |
Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories.
Topics: Antiviral Agents; Codon; Cytomegalovirus; DNA-Directed DNA Polymerase; Drug Resistance, Microbial; F | 1999 |
Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug.
Topics: Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Delayed-Action Preparations; | 1999 |
Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.
Topics: Antiviral Agents; Blotting, Northern; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA | 1999 |
Ganciclovir resistance in a heart transplant recipient infected by cytomegalovirus.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Microbial; Fo | 1999 |
Analysis of transcripts expressed from the UL47 gene of human cytomegalovirus.
Topics: Base Sequence; Blotting, Northern; Cytomegalovirus; Cytomegalovirus Infections; Fibroblasts; Foscarn | 1999 |
Neoglycolipid conjugates of foscarnet with enhanced antiviral activity in cells infected with human cytomegalovirus and herpes simplex virus type 1.
Topics: Animals; Antiviral Agents; Cells, Cultured; Cytomegalovirus; Foscarnet; Glycolipids; Herpesvirus 1, | 1999 |
A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; Fibroblasts; Foscarn | 2000 |
Antiviral activity of ganciclovir elaidic acid ester against herpesviruses.
Topics: Acyclovir; Administration, Oral; Animals; Antiviral Agents; Bromodeoxyuridine; Cell Line; Cytomegalo | 2000 |
Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events.
Topics: Cell Fusion; Cell Nucleus; Cells, Cultured; Coculture Techniques; Cycloheximide; Cytomegalovirus; Da | 2000 |
NeuroImages. "Owl's eyes" of CMV ventriculitis.
Topics: Adult; Antiviral Agents; Cerebral Ventricles; Cytomegalovirus; Cytomegalovirus Infections; Encephali | 2000 |
Ganciclovir resistance: a matter of time and titre.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; C | 2000 |
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Microbi | 2000 |
Growth phenotypes of cytomegalovirus isolates do not correlate with glycoprotein B, major immediate early genotypes or antiviral sensitivity.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; Cytopathogenic Effec | 2000 |
Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes.
Topics: Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; D | 2000 |
A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Re | 2000 |
Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient.
Topics: Antigens, Viral; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; | 2000 |
Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Topics: Acyclovir; Adolescent; Adult; Antifungal Agents; Antiviral Agents; Bone Marrow Transplantation; Cycl | 2000 |
Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma.
Topics: Adult; Aged; Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Female; | 2001 |
Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation.
Topics: Adult; Antiviral Agents; Chronic Disease; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis; Cyt | 2001 |
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; F | 2001 |
CMV retinitis: a clinical management update.
Topics: AIDS-Related Opportunistic Infections; Algorithms; Antiviral Agents; Cidofovir; Clinical Protocols; | 1996 |
Intraocular therapy for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Dr | 1996 |
CMV resistance: "more complicated than we thought".
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug Resistance, Microbia | 1996 |
Expression dynamics of human cytomegalovirus immune evasion genes US3, US6, and US11 in the blood of lung transplant recipients.
Topics: Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA Primers; DNA Pro | 2001 |
Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches.
Topics: Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Child; Cidofovir; Cytomegalovirus; C | 2001 |
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA.
Topics: Adolescent; Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resistance, Vi | 2001 |
Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.
Topics: Antiviral Agents; Codon; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; D | 2001 |
[In vitro susceptibility to ganciclovir and foscarnet of cytomegaloviruses].
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Drug Resistance, Viral; Fibroblasts; Foscarnet; | 2001 |
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Topics: Adult; Antiviral Agents; Cidofovir; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; Cytos | 2001 |
T-cell activation response to allogeneic CMV-infected endothelial cells is not prevented by ganciclovir or foscarnet: implications for transplant vascular sclerosis.
Topics: Antiviral Agents; Blood Vessels; Cytomegalovirus; Endothelium, Vascular; Foscarnet; Ganciclovir; Gra | 2002 |
Sequence analysis of UL54 and UL97 genes and evaluation of antiviral susceptibility of human cytomegalovirus isolates obtained from kidney allograft recipients before and after treatment.
Topics: Adult; Aged; Amino Acid Sequence; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA | 2001 |
[Cytomegalovirus sensitivity to anti-retroviral agents in patients infected with the human immunodeficiency virus with chorioretinitis in Spain].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Chorioretinitis; Cytomegalovirus; Cy | 2001 |
Clinicopathologic reports, case reports, and small case series: cytomegalovirus retinitis in patients with Good syndrome.
Topics: Agammaglobulinemia; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; DNA, Viral; | 2002 |
Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Microbial; Dr | 2002 |
A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Cytomegalovirus; Drug Resistance, Microbial; | 1992 |
Atypical healing of cytomegalovirus retinitis. Significance of persistent border opacification.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1992 |
CMV colitis in an immunocompetent adult.
Topics: Adult; Colitis; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Humans; Immunocompetence; Ma | 1992 |
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1991 |
Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; D | 1991 |
Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Drug Resistance, Microbial; Fibroblasts; Foscarn | 1991 |
Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment.
Topics: Adolescent; Adult; Antibodies, Viral; Bacterial Infections; Child; Cytomegalovirus; Cytomegalovirus | 1991 |
Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anti-cytomegalovirus agents.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Ester | 1991 |
Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient.
Topics: Adult; Antiviral Agents; Bone Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Drug Res | 1991 |
Increased efficacy of ganciclovir and foscarnet inhibition of cytomegalovirus replication in vitro by encapsulation in liposomes.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Drug Carriers; Fibroblasts; Foscarnet; Ganciclov | 1990 |
Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro.
Topics: Cytomegalovirus; DNA, Viral; Drug Synergism; Foscarnet; Ganciclovir; Phosphonoacetic Acid; Virus Rep | 1990 |
Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro.
Topics: Adenine; Adult; Antiviral Agents; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Cidofovir; Cytome | 1990 |
[Diagnosis and treatment of cytomegalovirus infections].
Topics: Acyclovir; Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Female; Foscarn | 1989 |
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; DNA-Directed DNA Polymerase; Drug Synergism; Fos | 1989 |
Foscarnet prophylaxis in marrow transplant recipients.
Topics: Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Humans; Nucleic | 1989 |
Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cytomegalovirus; Cytomegalovirus Infections; Drug | 1989 |
Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo.
Topics: Animals; Antiviral Agents; Cell Line; Cell Survival; Cytomegalovirus; Dose-Response Relationship, Dr | 1989 |
Immunological characterization of an early cytomegalovirus single-strand DNA-binding protein with similarities to the HSV major DNA-binding protein.
Topics: Cell Compartmentation; Cross Reactions; Cytomegalovirus; DNA-Binding Proteins; DNA, Single-Stranded; | 1987 |
Primate cytomegalovirus assembly: evidence that DNA packaging occurs subsequent to B capsid assembly.
Topics: Capsid; Cells, Cultured; Centrifugation, Density Gradient; Cytomegalovirus; DNA, Viral; Electrophore | 1988 |
Antiherpesvirus activity and mechanism of action of indolo-(2,3-b)quinoxaline and analogs.
Topics: Acyclovir; Animals; Antigens, Viral; Antiviral Agents; Cell Line; Cytomegalovirus; DNA-Directed DNA | 1988 |
Activity of the cytomegalovirus genome in the presence of PPi analogs.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Diphosphates; DNA Replication; DNA, Viral; Fosca | 1985 |
Identification and characterization of a major early cytomegalovirus DNA-binding protein.
Topics: Cell Nucleus; Cells, Cultured; Cytomegalovirus; Deoxyribonuclease I; DNA-Binding Proteins; DNA, Sing | 1986 |
Synthesis of cytomegalovirus DNA is an antiviral target late in virus growth.
Topics: Acyclovir; Antiviral Agents; Cell Line; Cytomegalovirus; DNA, Viral; Floxuridine; Foscarnet; Gancicl | 1987 |